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LIST OF ABBREVIATIONS 
AE   early polyadenylation 
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CDKs   cyclin-dependent kinase 
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CIN   cervical intraepithelial neoplasia 
COX-2  cyclooxygenase-2 
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CRPV   cottontail rabbit papillomavirus 
DBS   double-stranded break 
DCP2   decapping enzyme 2 
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DSS   disease specific survival 
E region  early region 
E1BS   E1 binding site 
E2BS   E2 binding site 
E6AP   E6-associated protein 
EGFR   epidermal growth factor 
eIF4G   eukaryotic translation-initiation factor 4G 
EMT   epithelial-to-mesenchymal transition 
ER   endoplasmatic reticulum 
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FF   fresh frozen 
FFPE   formalin-fixed paraffin-embedded 
FGFR1  fibroblast growth factor 1 
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FXR1   fragile X mental retardation-related protein 1 
GA   Golgi aparatus 
GTP   guanosintriphosphate 
HCV   hepatitis C virus 
HDACs  histone deacetylases 
HER2   human epidermal growth factor receptor 2 
HGL   high-grade lesion 
HNC   head and neck cancer 
HNSCC  head and neck squamous cell carcinoma 
HPV   human papillomavirus 
HR   high risk 
HSPGs  heparan sulphate proteoglycans 





IFN   interferon 
IRES   internal ribosome entry site 
IRF   interferon regulatory factor 
L region  late region 
LCR   long control region  
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LR   low risk 
MDM   mouse double minute 2 
MHCI   major histocompatibility complex I 
miRISC  microRNA-induced silencing complex 
miRNA  microRNA 
mlncRNA  mRNA-like noncoding RNA 
NCT   number of clinical trial 
NF-κB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NGS   next generation sequencing 
NIH   National Institute of Health  
ORF   open reading frame 
ORI   origin of replication 
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PABP   polyA-binding protein 
PACT   kinase-R-activating protein 
PAN   polyA nuclease 
PARN   poly(A)-specific ribonuclease 
PI3K   phosphatidylinositol-3-kinase 
pre-miRNA  precursor microRNA 
pri-miRNA  primary microRNA 
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RACE   Rapid Amplification of cDNA Ends 
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RRP   recurrent respiratory papillomatosis 
RT-qPCR  reverse transcription quantitative polymerase chain reaction 
SA   splice acceptor 
SCC   squamous cell carcinoma  
SD   splice donor 
SNP   single nucleotide polymorphism 
SSB   single-stranded break 
TCGA   The Cancer Genome Atlas 
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TNF   tumor necrosis factor  
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TSGs   tumor suppressor genes 
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Head and neck cancers represent a group of tumors with two different etiologies. 
The first type is associated with the viral HPV infection, the second one is 
virus-independent and it is associated with smoking and alcohol consumption as two main 
risk factors. Numerous studies show that HPV-positive tumors are more frequent in 
younger patients, as well as that the prognosis and overall survival of these patients is 
remarkably better. Therefore, the modification of the treatment is considered. For this, 
however, specific, sensitive and clinically relevant biomarkers for accurate identification 
of tumor etiology is needed. Suitable candidates for such biomarkers are miRNAs, small 
non-coding regulatory molecules stable in archived samples, that have been shown as 
differentially expressed in human cancers and the expression pattern seems specific for 
tumors of different origin. 
The submitted thesis focuses on miRNA profiling in HPV-positive and 
HPV-negative tonsillar tumors and cervical carcinomas with the aim to find out the 
differences between regulation of important carcinogenetic pathways of tumors of viral 
and non-viral etiology. Our data have shown very large heterogeneity of the miRNA 
expression profiles of these tumors. Despite the well characterized and uniform samples 
collection, we have found very small overlap of the HPV-specific miRNAs in comparison 
to both our model system and to other studies. Therefore, we focused on the reasons for 
such heterogeneity, this study has shown the importance of the homogeneity of analyzed 
samples and standardization of the type of clinical material and normalization approach 
for data analyses.  
Overall, the submitted thesis presents our results from miRNA research of 
HPV-related cancers. During the research, several important observations were made 
which allow for the improvement of the next experiments. Finally, the HPV-core 
miRNAs were identified and will be evaluated in a following project in a set of 
HPV-related and non-related samples from malignant tissues of other anatomical 







Nádory hlavy a krku představují skupinu nádorů dvojí etiologie. První skupinou 
jsou nádory asociované s infekcí HPV, druhou skupinou jsou nádory nevirové etiologie, 
které jsou spojeny s dvěma hlavními rizikovými faktory, a tím je kouření a konzumace 
alkoholu. Z publikovaných studií je zřejmé, že HPV-pozitivní nádory se vyskytují častěji 
u mladších pacientů a zároveň tito pacienti vykazují lepší prognózu a celkové přežívání. 
Z tohoto důvodu je zvažována modifikace léčby na základě etiologie nádorového 
onemocnění. Nicméně je důležité zajistit specifický, citlivý a klinicky významný 
biomarker pro přesné určení etiologie nádoru. Vhodným kandidátem pro takové 
biomarkery jsou miRNAs, jakožto malé nekódující regulační molekuly, které jsou stabilní 
i v archivních vzorcích, a jejichž rozdílná exprese byla detekována v řadě lidských nádorů 
a je specifická pro nádory různého původu. 
Předkládaná práce je zaměřena na miRNA profilování v HPV-pozitivních 
a HPV-negativních nádorech krčních mandlí a nádorech děložního hrdla s cílem najít 
rozdíly v regulaci důležitých karcerogenních drah nádorů virové a nevirové etiologie. 
Naše výsledky ukazují velkou heterogenitu v expresních profilech miRNAs u těchto 
nádorů. I přes využití velmi dobře charakterizovaného a jednotného souboru vzorků jsme 
detekovali malý překryv HPV-specifických miRNAs ve srovnání s naším modelovým 
systémem, a stejně tak ve srovnání s jinými studiemi. Z toho důvodu jsme hledali příčiny 
takové heterogenity a naše výsledky ukazují na důležitost stejnorodosti analyzovaných 
vzorků a standardizaci typu klinického materiálu a normalizačních přístupů pro 
vyhodnocování získaných dat.  
Souhrnně lze říci, že předkládaná práce představuje naše výsledky studia miRNA 
v HPV-asociovaných nádorech. Během výzkumu jsme narazili na několik důležitých 
poznatků, které nám pomůžou vylepšit další experimenty. Identifikovali jsme 
tzv. „HPV-core“ miRNA specifické pro HPV-asociované nádory a získaná data budou 
využita a zhodnocena v rámci následujícího projektu zabývajícího se miRNA analýzou 
HPV-asociovaných a neasociovaných nádorů dalších anatomických lokalizací. Dále pak 
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Head and neck cancer (HNC) is the ninth most common cancer type worldwide 
with more than 500 thousand of new cases annually (Ferlay et al., 2015; 
Gupta et al., 2016). In the Czech Republic, HNC is the twelfth most common tumor with 
almost 2000 new cases annually, and the incidence of the disease is still increasing 
(www.svod.cz, www.uzis.cz). HNC is often diagnosed in the late stage of the disease and 
thus the survival of patients is unsatisfying. The main risk factors for the development of 
this disease are smoking and alcohol consumption. In recent years, the role of HPV was 
noticed, especially with oropharyngeal tumors. The proportion of HPV-caused tumors 
varies worldwide, however, in the Czech Republic, around 68 % of the oropharyngeal 
tumors are high-risk HPV-positive (Tachezy et al., 2009). Although the disease is 
diagnosed mostly in the late stage, patients with HPV-associated tumors have better 
prognosis and overall survival (Dayyani et al., 2010), and the treatment could be 
optimized for each group according to the etiology. Therefore, it is important to find some 
specific and sensitive biomarker for the distinction of the carcinogenetic mechanisms of 
tumors of different etiologies. Such biomarker should help to improve diagnostics 
prognostic as well as therapeutic approaches.  
The thesis focuses on the study of head and neck tumors of both etiologies and on 
the determination of such biomarker. The suitable candidates for it could be miRNAs, 
short non-coding RNAs with posttranscriptional regulatory function. Their expression 
profiles differ in cancer tissues and in non-malignant ones, and the expression is also 
tissue specific. The expression of miRNA has been studied in various tumors, also in 
HNC, however, the distinction of etiology of these tumors has not been included yet. 
Thus, our research focused on the analysis of the group of well characterized HNC 
samples of single anatomical location in comparison to cervical cancer samples, where 
tumor relates to HPV infection in almost 100 %. Our results revealed some new findings 
in the field of miRNA research, which will, hopefully, contribute to determination of the 










2.1 Basic facts about human papillomaviruses 
Human papillomaviruses (HPVs) belong to the family Papillomaviridae and 
together with the family Polyomaviridae and Adenoviridae are referred as small DNA 
tumor viruses. HPVs have small non-enveloped, icosahedral capsid with 55 nm in 
diameter (Figure 2-1) which contains double-stranded DNA with the length up to 
8000 bp. These viruses infect epithelial cells of the skin or mucosa and may cause benign 
proliferations, such as papillomas or warts. Further, some types of HPVs have also 
oncogenic potential and participate in the oncogenic progression of premalignant lesions.  
Since the clinical manifestation of genital warts has been known since the times 
of Hippocrates, until the 50s of the 20th century they had not been considered as sexually 
transmitted disease. The first papillomaviruses were identified by Shore and Hurst 
in 1933 in the cottontail rabbit (cottontail rabbit papillomavirus, CRPVs) 
(Shope and Hurst, 1933). Soon afterwards, Rous and Beard described the oncogenic 
potential of this papillomavirus (PV) type (Rous and Beard, 1935). The viral particles in 
genital warts were first demonstrated by electron microscopy in 1969 (Waterson and 
Almeida, 1969). The milestone in the HPVs research came at the beginning of the 80s of 
the 20th century with the isolation of HPV16 and HPV18 from the cervical carcinoma 
cells in the laboratory of Harald zur Hausen (Durst et al., 1983; Boshart et al., 1984). 
Since then many research groups became interested in the investigation of HPVs, their 
molecular biology, the relation to the carcinogenesis and the research aimed at 
development of the vaccine. In 2008, Harald zur Hausen received the Nobel Prize in 
Physiology or Medicine for his discovery of HPV causing cervical cancer.  
          
Figure 2-1: (A) Model of HPV16 capsid (Cardone et al., 2014); (B) Electron micrograph 
of papillomavirus particles (Doorbar et al., 2015). 
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2.1.1 Viral classification 
With the development of the molecular biology methods in the 1980s, the new 
period of HPV research started. To date, up to 200 HPV types have been identified along 
with over 100 of animal PV types including mammals, birds, snakes or turtles 
(http://pave.niaid.nih.gov). For PVs classification, the gene for the major capsid protein 
L1 is used standardly since the L1 open reading frame (ORF) is the most conserved region 
in HPV genome (IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans, 2007). To be identified as a new papillomavirus type, the DNA sequence of the 
L1 ORF must differ in more than 10 % from the closest known PV type (IARC Working 
Group on the Evaluation of Carcinogenic Risks to Humans, 2007). HPVs are organized 
into 5 genera (Figure 2-2). The largest PV groups are: Alpha-, Beta-, 
Gamma-papillomaviruses and also Nu- and Mu-papillomaviruses.  
Alpha-papillomaviruses are classified as cutaneous and/or mucosal types, 
according to the tissue tropism. Based on the oncogenic potential, HPV types are 
classified as high-risk (HR), which can cause pre- and malignant lesions, and low-risk 
(LR), causing benign lesions. The most frequent mucosal LR-types are HPV6 and 11 
which cause genital warts (condyloma accumitatum) or recurrent respiratory 
papillomatosis (RRP) (Ball et al., 2011; Omland et al., 2014). The most common 
HR-HPVs are HPV16, 18, 31, 33, 45, 51 or 58. Many studies confirmed the role of 
HR-HPV types in the development of cervical cancer and cancer of other anogenital 
regions (Rubin et al., 2001; Daling et al., 2002; Munoz et al., 2003), as well as their 
etiological role in the development of head and neck cancer (Snijders et al., 1996; 
Gillison et al., 2000). 
Beta-papillomaviruses mostly include cutaneous types of HPVs and were found 
to be associated with the cutaneous squamous cell carcinomas (SCC) of 
epidermodysplasia verruciformis (EV) patients (Pfister, 2003). EV is a hereditary skin 
disease with characteristic skin lesions which can progress to SCC and is associated 
mostly with HPV5 and 8, rarely with HPV14, 17, 20 or 47. However, 
beta-papillomaviruses are also widely spread on the skin of healthy population with the 
prevalence up to 91 % and the most prevalent type HPV23 (de Koning et al., 2009). 
Gamma-papillomaviruses comprehend mostly cutaneous types and are represented 
by e. g. HPV4, 48, 50 or HPV60. 





Figure 2-2: Phylogenetic relationship between human papillomaviruses. 
Alpha-papillomaviruses are classified as low-risk cutaneous (brown), low-risk mucosal 
(yellow) and high-risk mucosal (pink). The highlighted types (text in red) are confirmed 
as “human carcinogens”. Adapted from Egawa et al., 2015. 
 
2.1.2 Genome of human papillomaviruses 
HPVs´ viral capsid contain approximately 8 kb long circular double-stranded 
DNA genome, which is divided into three main regions and contains eight or nine ORFs 
(Figure 2-3); the early region (E) that encodes the early proteins E1-E7, the late region 
(L) that encodes two capsid proteins L1 and L2, and the upstream regulatory region 
(URR), also known as long control region (LCR), which contains regulatory sequences, 
such as promotor and enhancer elements as well as the viral origin of replication (ORI) 
(Seedorf et al., 1985). The regions are separated by two polyadenylation (pA) sites; early 
pA (AE) and late pA (AL). In the early stages of the viral life cycle, the viral early 
transcripts are driven by early promotor (e.g. p97 in HPV16, p99 in HPV31) (Smotkin and 
Wettstein, 1986; Ozbun and Meyers, 1998) and polyadenylated at the pAE. As the cell 




differentiates, the late promotor (e.g. p670 in HPV16, p742 in HPV31) 
(Grassmann et al., 1996; Ozbun and Meyers, 1998) is activated and the shortened variants 
of the early proteins E1, E2 and E4 are transcribed. During the terminal differentiation of 
the host cells, the activity of pAE is downregulated, the transcription of the true late region 
is activated and the mRNAs for L1 and L2 proteins polyadenylated at the pAL are 
transcribed (reviewed in Johansson and Schwartz, 2013). The genome of all HPVs is 
transcribed from a single DNA strand and the polycistronic mRNAs undergo alternative 
splicing utilizing various splice sites.  
The number of ORFs differ among HPVs, however, the core genes encoding the 
early proteins E1 and E2 involved in replication, and genes for late proteins L1 and L2 
involved in packaging, are well-conserved across the HPV types. The early region further 
encodes other four early genes (E4, E6, E7, E5). In some HPV types, the fusion protein 
E8^E2C has been proven (Stubenrauch et al., 2000; Lace et al., 2008; 
X. Wang et al., 2011; Sankovski et al., 2014).   
 
Figure 2-3: Illustration of the HPV16 genome organization (Stanley, 2012). 
 
The E1 protein has helicase and ATPase activity, it is necessary for viral 
replication when it binds to the specific viral DNA sequence (E1 binding site, E1BS) and 
together with the protein E2 it initiates the DNA unwinding (Wilson et al., 2002; reviewed 
in Bergvall et al., 2013). The E2 protein has triple role. First, its domain in carboxyl 
terminus binds to four conserved E2 binding sites (E2BSs) in the LCR sharing 
a consensus DNA sequence. The binding of different levels of this protein to E2BSs 
regulates transcription of the early viral genes, including E2 itself (Romanczuk et al., 
1990). The E2 protein is also a negative regulator of the expression of the main HPV 
oncoproteins E6 and E7. Furthermore, E2 protein binds to the specific motifs in the viral 
genome and attaches it to the mitotic chromosome. This mechanism ensures the right 




segregation of the viral genome between daughter cells during cell division (Bastien and 
McBride, 2000; McBride et al., 2006). The middle region of the protein supports the 
stability of E2 proteins itself and is required for the efficient nuclear localization 
(Zou et al., 2000). Finally, the N-terminus is essential for the interaction with the protein 
E1 and as such it plays role in regulation of the viral replication. Recently, 
Cruz-Gregorio et al. have revealed that proteins E1 and E2 modulate cellular redox state 
and thus influence DNA damage, which could be an important event in establishment of 
persistent infection and potential cellular transformation (Cruz-Gregorio et al., 2018).  
The gene for E4 protein overlaps in the HPV genome with the E2 gene, but it is 
expressed in a different ORF. The protein E4 is expressed as a fusion protein E1^E4 
(Doorbar et al., 1990; X. Wang et al., 2011) and the most abundant expression occurs 
during the later stages of the viral life cycle (Doorbar et al., 1997; Peh et al., 2002; 
Middleton et al., 2003), therefore the expression of the E4 protein is consider as 
a biomarker of vegetative viral genome amplification (Peh et al., 2002). Similarly, 
Wilson et al. wanted to determine the role of E1^E4 protein of HPV18. They revealed 
that this E1^E4 protein plays role in regulating the HPV late functions, however, it also 
participates in the early phase of the replication cycle (Wilson et al., 2007). Contrary to 
this study, Fang et al. have reported that the expression of full-length E1^E4 protein is 
not necessary for efficient genome amplification of HPV11 (Fang et al., 2006). That 
suggests that there may exist type-specific differences between the functions of E1^E4 
proteins. The E1^E4 protein also plays role in virus escape form the epithelial cells, since 
it associates with keratin filaments and participates on reorganization of the keratin 
cytoskeleton (Wang et al., 2004; McIntosh et al., 2010). Thereby, it disrupts structural 
integrity of infected cells and facilitates the release of newly synthetized virus particles. 
Several types of HPV (e.g. HPV16, HPV18 or HPV31) express also a spliced 
mRNA that links the E8 gene with the E2 gene and encodes the fusion protein E8^E2C 
(Stubenrauch et al., 2000; Lace et al., 2008; Wang et al., 2011; Sankovski et al., 2014). 
This protein functions as a repressor of viral replication and transcription, and it interferes 
with the E2-dependent transcriptional activation by the full-length E2 proteins 
(Stubenrauch et al., 2001; Lace et al., 2008; Straub et al., 2014). 
The HPV early proteins E5, E6 and E7 are the main viral oncoproteins, the 
mechanisms of their function are described in detail in 2.1.4. 




HPVs encode two structural proteins - the major late protein L1 and the minor late 
protein L2. The protein L1 forms 72 pentameric capsomers and together with up to 
72 single L2 proteins forms an infectious virion (Buck et al., 2008). The L1 protein 
facilitates the attachment with the host cell, whilst the L2 protein is essential for the viral 
genome encapsidation or it participates in multiple steps during the viral entry to the host 
cell (reviewed in Buck et al., 2013; Wang and Roden, 2013). Moreover, the major capsid 
protein L1 is able to spontaneously self-assemble into “virus-like particles” (VLPs) 
exhibiting morphological and immunological features of native virions (Zhou et al., 1991; 
Ghim et al., 1992). Since the VLPs are only the empty capsids without the infectious 
genome, they are used for development of VLP-based vaccines (Kirnbauer, 1996; Vonka 
and Hamsikova, 2007). Until 2015, two types of VLP-based prophylactic vaccines were 
available in the Czech Republic - bivalent vaccine CervarixTM, designed to prevent 
against the two most common HR-HPV types 16 and 18, and quadrivalent vaccine 
GardasilTM (also known as Silgard®), targeting additionally against HPV6 and HPV11 
causing genital warts and low-grade lesions (reviewed in Cutts et al., 2007). After years 
of development, the current quadrivalent vaccine was enlarged to the nonavalent vaccine 
targeting five additional HR-HPV types (HPV31, -33, -45, -52, -58) and as Gardasil 9® 
was licensed in 2014 (Pils and Joura, 2015). This nonavalent vaccine has been available 
in the Czech Republic since 2015. The vaccination in the Czech Republic is endowed for 
the young of both genders at the age of 13-14 years. 
 
2.1.3 Life cycle of HPVs  
Human papillomaviruses are intraepithelial pathogens. Their life cycle is strictly 
dependent on differentiation process of infected keratinocytes and on the replication 
apparatus of the host cell (Figure 2-4). HPVs infect the basal layers of epithelium through 
the small wounds or abrasions. The mitotic cell division, which occurs during the wound 
healing, is necessary for the entry of the virus into the host cell and into the cell nucleus 
(Pyeon et al., 2009). The virus initially bounds to the heparan sulphate proteoglycans 
(HSPGs) situated on the basement membrane of epidermis (Combita et al., 2001; 
Giroglou et al., 2001). The interaction between the HPV capsid and the heparan sulphate 
on the membrane is mediated by the HPV protein L1 and is necessary for the efficient 
infection of the cells (Knappe et al., 2007; Surviladze et al., 2015). This attachment 
induces the conformational changes in the virus capsid leading to the exposure of the 




amino terminal portion of capsid protein L2, which is then cleaved by convertase furin 
and other, non-HSPGs receptors, are uncovered (Richards et al., 2006; Day and Schiller, 
2009). The exact way, how the virus enters the host cell and reaches the nucleus, is 
unknown, however Spoden et al. suggest that the HR-HPV types share similar novel 
requirements for the endocytic mechanism of the entry (Spoden et al., 2013) independent 
on the well-studied clathrin-, caveolin- or dynamin-mediated pathways.  
In the basal cells of the epithelium, the virus maintains its genome in low copy 
number as an extrachromosomal genome called episome. The viral DNA replication is 
regulated by the proteins E1 and E2 and the genome is amplified to 50-100 copies per 
cell (Parish et al., 2006; McBride, 2008), while the expression of the potent viral 
oncogenes E6 and E7 is under very tight control. When the host cells begin to differentiate 
the viral gene expression and DNA replication is upregulated, the expression of E6 and 
E7 proteins allows the infected cell to re-enter the S-phase of the cell cycle and the 
genome copy number increases to thousands. During the terminal differentiation of the 
epithelium, the viral late promotor is activated and the genes encoding the capsid proteins 
are expressed. Afterwards, the viral genomes are encapsidated and exit the cell along with 
the shredding keratinocytes as an infectious particle. The life cycle of HPVs is at least 
three-weeks long and the release of the viral particles does not cause the cell death.  
 
Figure 2-4: Life cycle of human papillomaviruses (Moody and Laimins, 2010). 
 
2.1.4 Human papillomaviral oncoproteins 
2.1.4.1 Protein E6 
Protein E6 is - along with the other protein, E7, one of the most important HPV 
oncoprotein and it participates in cellular transformation. It targets critical regulators of 
cellular processes, which leads to unlimited proliferation, evasion of apoptosis, induction 




of invasive and metastatic properties or sustained angiogenesis (McLaughlin-Drubin and 
Munger, 2009b). The most well-characterized function of this protein is the ability to 
interfere with the activity of the protein p53. Protein p53 is a tumor suppressor regulating 
cellular pathways which mediate cell cycle arrest or induce cellular apoptosis in response 
to DNA damage or other cellular stress. HPV oncoprotein E6 forms a complex with p53 
and cellular E3 ubiquitin ligase called E6-associated protein (E6AP). This results in 
ubiquitination and degradation of the p53 via proteasome (Scheffner et al., 1990; 
Mortensen et al., 2015). The E6AP interacts with the LXLL motif situated in the amino 
terminal region of the E6 oncoprotein. 
Protein E6 plays role also in p53-independent pathways resulting in cellular 
transformation. One of them is the ability to activate telomerase (hTERT), which 
maintains the telomeric DNA at the end of linear chromosomes and, therefore, telomeres 
are not shortened upon each cell division, which leads to immortalization of the host cells. 
Veldman et al. published that HR-HPV E6 protein activates the hTERT promoter via 
interactions with c-Myc and thus increases the enzyme activity (Veldman et al., 2001; 
Veldman et al., 2003). In addition, there is also some evidence that protein E6 associates 
with the repressor of the hTERT promoter NFX1 leading to the increased hTERT 
transcription (Gewin et al., 2004; Katzenellenbogen et al., 2007).   
The carboxyl terminal region of the E6 protein contains PDZ-binding motifs 
which interact with the specific PDZ domains of cellular proteins. These proteins often 
play role in signaling pathways and regulation of cellular polarity. The interaction of E6 
and proteins harboring PDZ domains leads to their degradation and thus cellular 
transformation (Nguyen et al., 2003; Watson et al., 2003). Webb Strickland et al. have 
also reported that E6 interaction with PDZ domains of several proteins modulates the 
activation and nuclear localization of transcriptional regulator YAP1 and thus contributes 
to oncogenesis (Webb Strickland et al., 2018). E6 proteins of LR-HPVs lack the ability 
to associate with the PDZ proteins (Kiyono et al., 1997). 
HR-HPV protein E6 can also interact with other cellular proteins such as 
interferon regulatory factor 3 (IRF-3), which normally activates the expression of 
interferons (IFNs) - cytostatic cytokines playing role in immune response to viral 
infections. The association of E6 protein and IRF-3 leads to the inhibition of IRF-3 
transcriptional activity (Ronco et al., 1998). Further, E6 protein interacts with the 
transcriptional coactivators CREB-binding protein and p300 (CBP/p300), tumor 




suppressors promoting apoptosis and inhibition of the cell cycle progression and cellular 
differentiation (Goodman and Smolik, 2000). The binding of the E6 protein to CBP/p300 
displaces the protein p53 from its binding site on CBP/p300 and thus it is another viral 
mechanism how to abrogate the p53 function (Zimmermann et al., 1999). 
 
2.1.4.2 Protein E7 
Other important protein of human papillomaviruses is oncoprotein E7 which along 
with the oncoprotein E6 participates in the cellular transformation. It is a small 
polypeptide containing two conserved regions CR1 and CR2 at the amino terminal 
domain. These regions are necessary for the transforming activities of the protein and 
have the sequence similarities with adenovirus protein E1A as well as polyomavirus 
SV40 large T antigen. The main target of E7 is retinoblastoma protein Rb and other 
“pocket proteins” associated with pRb, namely p107 and p130. Protein Rb is a tumor 
suppressor protein regulating cell cycle progression since it controls the G1/S transition. 
It forms the pRb-E2F repressor complex which arrests the cell cycle progression into the 
S-phase. When the cell is ready to divide, Rb protein is phosphorylated by 
cyclin-dependent kinases (CDKs), the transcription factor E2F is released from the 
repressor complex and the cell cycle can progress to the S-phase. During M/G1 transition, 
pRb is dephosphorylated and it returns into the “active” hypophosphorylated state with 
linked E2F (reviewed by Munger and Howley, 2002). 
The primary mechanism of E7-mediated cell cycle deregulation is the association 
of E7 protein with the hypophosphorylated pRb and its targeting for the proteasomal 
degradation through the interaction with cullin 2 ubiquitin ligase complex (Huh et al., 
2007). The pRb is bound to the conserved LXCXE motif in CR2 region of E7. 
Simultaneously, the transcription factor E2F is released from the complex with pRb and 
the E2F-mediated transcription is activated facilitating the cell cycle progression leading 
to cellular transformation. 
In addition to pRb, the oncoprotein E7 interacts also with other cellular proteins 
involved in the cell cycle regulation. Its inactivation leads to the cellular transformation, 
including cyclin A and E or cyclin-dependent kinase inhibitor p21CIP1 and p27KIP1 both of 
which are activated by anti-proliferative signals and contribute to cell-cycle arrest 
(McLaughlin-Drubin and Munger, 2009a). Moreover, it has been also shown that E7 can 
attract the histone deacetylase (HDACs) proteins to the chromatin and thus promote 




E2F-mediated transcription (Longworth et al., 2005). The protein E7 binds to the HDACs 
through the zinc-finger-like regions at the carboxyl terminus. Further, the binding of the 
E7 protein to HDACs is important for maintenance of the extrachromosomal form of 
HPV in undifferentiated keratinocytes (Longworth and Laimins, 2004). Analogous to 
protein E6, the oncoprotein E7 interacts with the interferon regulatory factor 1 (IRF-1) 
through its pRb-binding domain (Um et al., 2002). IRF-1 is a transcription factor 
influencing expression of interferon β (IFN-β) and thus the viral ability to escape the host 
cell immunity.    
 
2.1.4.3 Protein E5 
Papillomaviral protein E5 is the least understood of the three papillomaviral 
oncoproteins. It is rich in hydrophobic amino acid clusters and localized to membranes 
of Golgi aparatus (GA) and endoplasmatic reticulum (ER) (Oetke et al., 2000; 
Disbrow et al., 2003). The characteristics of bovine papillomavirus 1 (BPV1) E5 and 
HPV16 E5 have been studied the most. Although E5 proteins of these two types show 
minimal sequence similarity with each other and HPV16 E5 is almost twice as large, they 
both transform cells and overlap in their function and targets.  
E5 protein is not encoded in all HPV types, however, it is likely that it plays a 
significant role in viral replicative life cycle and that its presence in viral genome 
correlates with the risk of cancer. This suggests that it contributes to the function of 
oncoproteins E6 and E7 and hence also to the human carcinogenesis (Bravo and Alonso, 
2004; Schiffman et al., 2005). It has been shown that HPV16 and HPV18 E5 increases 
the level of the receptor of epidermal growth factor (EGFR) and in this way sensitizes the 
cells to EGF and stimulates the transformation and mitogenic activity of the cells 
(Tomakidi et al., 2000; Kivi et al., 2008; Wasson et al., 2017). HPV16 E5 also influences 
the EGFR downstream signaling pathways and, through that, also the expression of 
a number of oncogenes such as c-jun, c-fos, cyclooxygenase-2 (COX-2) or vascular 
endothelial growth factor (VEGF) contributing to the independent growth (Chen et al., 
1996; Kim et al., 2006; Kim et al., 2009). Further, HPV16 E5 downregulates the activity 
of cell cycle inhibitors p21 and p27 (Tsao et al., 1996; Pedroza-Saavedra et al., 2010).  
HPV16 E5 influences the host cells also in EGFR-independent way when it 
promotes the cell-cell fusion and contributes to transformation by increasing the cellular 
DNA content. Hu et al. demonstrated that HPV16 E5 is necessary for the formation of 




bi-nucleated cells which play an initiating role in the early stages of HPV-induced cellular 
transformation (Hu et al., 2009). Furthermore, HPV16 E5 interacts with the 16K subunit 
of vacuolar ATPase (V-ATPase) (Conrad et al., 1993) which leads to the decreasing 
acidification of endosomes followed by increased recycling of EGFR to the cell surface 
and constitutive signaling (Straight et al., 1995). HPV16 E5 also plays role in evading of 
immune response since it interacts with the heavy chain of human major 
histocompatibility complex I (MHCI) antigen and thus restricts its transport to the cell 
surface (Ashrafi et al., 2005; Ashrafi et al., 2006). 
 
2.1.5 Epidemiology  
2.1.5.1 Epidemiology of HPV infection 
HPV infection is the most common viral sexually transmitted infection worldwide 
and it is estimated that approximately 440 million individuals are infected with HPV 
(Malik et al., 2014). HPV is most often transmitted horizontally by sexual contact, but 
the penetrative sex is not required. Further, the vertical transmission from infected 
mothers is also possible, but it is not very common (Burchell et al., 2006). Most of the 
infections are inapparent and are spontaneously cleared with the immune system of the 
host without clinical manifestation, nevertheless the clearance rate of HR-HPVs is lower 
than that of the low risk types (Molano et al., 2003). Only about 25 % of all individuals 
infected with HPV develop precancerous neoplasia and fewer than 1 % progress to the 
invasive cancer (Malik et al., 2014). Based on the meta-analysis published by Bruni et al., 
the HPV prevalence worldwide among women with normal cytological findings was 
~11 % before the introduction of vaccination (Bruni et al., 2010), but it varied between 
different continents. The HPV prevalence was the lowest among females who reported 
never having sex and significantly increased with increasing age (Hariri et al., 2011). 
The most prevalent types in the Eastern Europe were HR-HPV types 16, 31, 18, 39, 33, 
and 66 and from the low risk types it was HPV6 (Bruni et al., 2010). In the Czech 
Republic the HPV prevalence was higher than in other countries of Eastern Europe 
(Tachezy et al., 2013) and the types detected in the Czech population (HPV16, 56, 39, 
45, 18, and 51) were different than those reported by Bruni et al. (Bruni et al., 2010). 
In 2016, Markowitz et al. published a study reporting a decrease of prevalence of 
quadrivalent HPV vaccine types after introduction of vaccination in the population of 
United States (Markowitz et al., 2016). There was a 64% decrease in the prevalence 




among females aged 14 to 19 years and 34% decrease among those aged 20 to 24 years. 
Similar results were reviewed in meta-analysis by Drolet et al. (Drolet et al., 2015) which 
reflects promising effect of vaccination programs.  
Beside HPV DNA, the useful epidemiologic marker of HPV infection is the 
detection of antibodies to antigens derived from HPV-specific proteins. The presence of 
antibodies specific to L1 VLPs reflects the past and cumulative exposures to the virus 
(Herrero et al., 2003; Zhao et al., 2005; Tachezy et al., 2009). Our laboratory published 
a large population-based seroepidemiological study which revealed that the 
seroprevalence in the Czech Republic is age-dependent and for the most common 
HR-HPV types reaches the maximum in 30-39-year-old women and 50-59-year-old men 
(Hamsikova et al., 2013). This study also provided evidence-based data supporting the 
implementation of HPV vaccination in the Czech Republic before the age of 13. 
Antibodies specific to HPV E6 and E7 are rarely present in healthy individuals but their 
prevalence is high in patients with invasive malignant diseases associated with HPV 
infection (Zumbach et al., 2000).  
 
2.1.5.2 Epidemiology of HPV-related carcinomas          
More than 14 million of cancer cases are diagnosed each year worldwide 
(Ferlay et al., 2015) and about 5 % is associated with the HPV infection (Plummer et al., 
2016). Cervical cancer is the fourth most common cancer in women worldwide and the 
seventh overall with over 500 thousand new cases in 2012 (Plummer et al., 2016), and is 
almost in 100 % etiologically linked to the HPV infection. For the development of the 
premalignant lesions and/or invasive carcinomas the persistent infection with HR-HPVs 
is necessary (Schiffman and Kjaer, 2003; Radley et al., 2016). An important factor for 
the progression of precancerous lesions is HPV type. The most frequent type in invasive 
carcinomas is HPV16 which is responsible for 40 % of high-grade lesions and more than 
a half of the cervical cancer cases (Crow, 2012; Schiffman and Wentzensen, 2013). 
The second most common carcinogenic type is HPV18 (Figure 2-5).  
A recent study of Schütze et al. demonstrated that HPV types with lower 
prevalence in cervical cancer and precursor lesions show reduced in vitro immortalization 
capacity and require more genetic host cell aberrations than the more prevalent types 
(Schutze et al., 2016).  




Further, to the persistent HPV infection and the progression of the disease 
contribute behavioral factors such as smoking, multiparity or sexual behavior 
(International Collaboration of Epidemiological Studies of Cervical Cancer et al., 2006; 
International Collaboration of Epidemiological Studies of Cervical Cancer, 2006; 
International Collaboration of Epidemiological Studies of Cervical Cancer, 2009). In the 
Czech Republic, the incidence of the cervical carcinoma stagnates in time with more than 
800 new cases in 2014 (http://svod.cz). The most prevalent type in Czech women is HPV 
16 which was detected in 43 % of cervical precancerous lesions and in 73 % of cervical 
carcinomas (Tachezy et al., 2011).  
Although the majority of HPV-related cancers are cervical, the viral infection can 
also lead to the carcinomas in other parts of the body (Figure 2-5). These cancers include 
those of vagina, vulva, anus, and penis, with more than 110 thousand of new cases in 
2012 (Plummer et al., 2016). There is also the evidence that HPV infection is related to 
the head and neck tumors, mainly oropharyngeal cancer. The part about head and neck 
tumors is discussed in chapter 2.2. 
Beside the mucosal types from the genus alpha-PVs, the cutaneous HPV types 
might play role in the pathogenesis of cutaneous cancer. In 2009, two beta-PVs, HPV5 
and HPV8, were classified as possibly carcinogenic in patients with epidermodysplasia 
verruciformis with a high susceptibility to beta-PVs and skin cancer (Bouvard et al., 
2009). 
     
Figure 2-5: HPV and cancer. Left - percentage distribution of HPV types is cervical 
cancer. Right – comparison of total number of cancer cases at different anatomical 
location and those related to HPV infection (Crow, 2012). 
 




2.1.6 Molecular mechanisms of HPV-associated carcinogenesis       
As mentioned in 2.1.5.2, persistent viral infection with HR-HPV type, especially 
HPV16/18, is a precondition for the development of premalignant lesions and their 
progression to malignant carcinomas (Radley et al., 2016). Cervical cancer is preceded 
by premalignant changes of different histological grading known as cervical 
intraepithelial neoplasia (CIN). A low-grade lesion CIN (LGL, CIN1) typically 
disappears within a few months and is caused by transient HPV infection. The cellular 
proliferative and antiapoptotic effects of cervical inflammation in combination with the 
low-level expression of HPV oncogenes contribute to the progression of this mild 
dysplasia to the high-grade lesions characterized as moderate dysplasia CIN2 and/or 
severe dysplasia CIN3 (Williams et al., 2011). Although most of women are at some time 
in their lives infected with HPV, the progression into the invasive carcinoma occurs only 
in the minority of them. It suggests that some other factors are contributing to the cancer 
development on molecular level such as genomic instability, HPV DNA integration into 
the host genome, or epigenetic alterations. The mechanisms of HPV-related 
carcinogenesis was studied mostly in cervical cancer, however, the key events are similar 
also for the carcinomas of head and neck region.    
 
2.1.6.1 Genomic instability 
Primary immune response to the viral infection or infection by other pathogens is 
an inflammation (Williams et al., 2011). Chronic inflammation is referred to as a cancer 
promotor (Coussens and Werb, 2002) because it induces cell proliferation and increases 
formation of reactive oxygen species (ROS) or reactive nitrogen species (RNS) which 
leads to the DNA damage such as DNA single-stranded breaks (SSB) and 
double-stranded breaks (DSBs). It also increases accumulation of mutations and thus 
genomic instability. However, infection with HPV does not cause a typical immune 
response since the virus infects the basal epithelial cells, and the HPV life cycle is nonlytic 
thus the inflammation leading to oxidative stress does not occur. Moreover, the specific 
immune response is also influenced in HPV-associated preneoplastic lesions where the 
right function of antigen presenting cells is decreased (Herfs et al., 2009). The splice 
variant of the viral oncoprotein E6, E6*, can increase ROS levels in keratinocytes which 
leads to the increased DNA damage (Williams et al., 2014). Alcohol consumption and 
tobacco smoking are other factors which contribute to the induction of oxidative stress in 




infected cells resulting in DNA damage (Tsuchiya et al., 1993). Mehta and Laimins 
(Mehta and Laimins, 2018) have revealed that HPVs preferentially recruit DNA repair 
factors to viral genomes, utilize them for the induction of viral genome amplification upon 
epithelial differentiation (Gillespie et al., 2012; Anacker et al., 2014; Spriggs and 
Laimins, 2017) and rapid reparation of DNA breaks in viral genome. Further, HPV 
maintains this deregulated state with the expression of the oncoprotein E6 which mediates 
the degradation of p53, a cellular guardian of the cell cycle, and thus disrupts the repair 
mechanisms of the cellular DNA. Proteins E6 and E7 also induce the accumulation of 
abnormal numbers of centrosomes leading to the development of aneuploidy and genomic 
instability (Duensing et al., 2000; Duensing and Munger, 2002).  
 
2.1.6.2 HPV DNA integration 
Regardless the anatomical site, the mechanism of HPV-induced carcinogenesis 
relies on the function of the main HPV oncoproteins E6 and E7. As discussed in 2.1.4, 
HPV oncoproteins associate with the tumor suppressors p53 and pRb leading to their 
degradation and thus deregulation of the tumor suppressive function. The integration of 
the viral DNA into the host genome is considered as a key event in the HPV-related 
carcinogenesis. The risk of virus integration depends on the level of DNA damage 
because this event requires DSBs in both the host and virus DNA since HPV do not 
encode any integrase (Pett and Coleman, 2007). The frequency of integration is also 
different for each HR-HPV type. The HPV16 is found integrated in 55 % of cervical 
tumors, by contrast, HPV18 is found integrated in 92 % and HPV31 in 14 % of those 
tumors (Vinokurova et al., 2008). The study of Vinokurova et al. also suggests that the 
integration is a consequence of the deregulated expression of oncoproteins E6 and E7 
(Vinokurova et al., 2008). Moreover, the recent study of Schütze et al. has revealed the 
differences in in vitro E6/E7 immortalization capacity of different HR-HPV types where 
in cells infected with HPV types with reduced immortalization potential 
(HPV45, -51, -59, -66, -70) higher number of genetic host cell aberrations was found 
necessary for inducing of immortalization (Schutze et al., 2016). This may explain the 
fact that there are less cervical carcinomas induced by these HPV types in population. 
The frequency of HPV16 integration increases with the severity of the cervical 
neoplasia, however, only extrachromosomal forms of the virus were also detected in the 
invasive lesions (Klaes et al., 1999; Arias-Pulido et al., 2006; Vinokurova et al., 2008). 




It seems that the integration is important in the HPV-associated oncogenesis, albeit not 
necessary, and other mechanisms could lead to the cell transformation. In high-grade 
cervical lesions, the region of early genes E2 and E8^E2 are often disrupted or lost during 
the HPV integration, leading to the increased upregulation of the expression of the E6 and 
E7 which favors oncogenesis (Jeon et al., 1995; Klaes et al., 1999; Tsakogiannis et al., 
2015). Further, the integration into the E1 or L2/L1 gene regions was also observed in 
high-grade malignancies, as well as in low-grade lesions (Li H. et al., 2013; 
Tsakogiannis et al., 2015). Nevertheless, the viral oncoproteins E6 and E7 are always 
retained and are actively transcribed (Akagi et al., 2014). 
In the cases of carcinoma with extrachromosomal form of the virus, the elevation 
of the copy number of viral episome represents one of the options how the expression of 
viral oncogenes might be increased (Gray et al., 2010). However, other studies have not 
observed the increased number of viral oncogenes in cancers with episomal form of HPV. 
Similarly, our results indicate this tendency, but the results were not statistically 
significant (Pokryvkova et al., manuscript in preparation). Other possibilities how the 
expression of the viral oncoproteins E6 and E7 can be increased is the epigenetic 
regulation of the binding sites in URR for the negative regulator E2 (discussed in 2.1.6.3) 
which was suggested in cervical tumors by Cheung et al. (Cheung et al., 2013), or the 
mutations in the LCR that would preclude the right expression and binding of E2 protein 
(Chaiwongkot et al., 2013; Cheung et al., 2013; Kahla et al., 2014). Both of these 
alternative mechanisms were studied also in our laboratory; however, our study has not 
revealed mutations in the E2 binding sites (Pokryvkova et al., manuscript in preparation), 
and, in contrary to our expectations, the increased methylation level of E2BSs was 
observed in tumors with integrated HPV genome (Pokryvkova et al., manuscript in 
preparation).  
Two types of integration have been observed in HPV-associated neoplasms 
(Jeon et al., 1995). In type I, there is a single copy of viral genome integrated into a host 
chromosome, whilst in type II a tandem of several viral genomes is integrated with the 
last copy being disrupted. In type II, mostly the 3´ end of the viral genome is 
transcriptionally active. The other copies are intact, however transcriptionally inactive 
(Van Tine et al., 2004). It has been suggested by Kalantari et al. (Kalantari et al., 2008) 
that the other copies are silenced by epigenetic modifications. In agreement with 
Kalantari et al. and Chaiwongkot et al. (Chaiwongkot et al., 2013), we observed 




hypermethylation of LCR in type II integrated HPVs (Pokryvkova et al., manuscript in 
preparation). Moreover, Dooley et al. (Dooley et al., 2016; Warburton et al., 2018) have 
recently revealed that tandemly integrated repeats of HPV genome can develop into a 
Brd-4 dependent super-enhancer-like element. Brd4 is a chromatin binding factor which 
regulates cellular transcription by binding to the super-enhancer regions - clusters of 
traditional enhancers often associated with expression of oncogenes. The authors detected 
highly enriched marker Brd4 at tandemly integrated copies of HPV16 in cells of cervical 
neoplasia cell line W12 and have shown that it drives the strong E6/E7 oncogenes 
transcription promoting the development of neoplasia (Dooley et al., 2016; 
Warburton et al., 2018).   
HPV integration sites are thought to be a randomly distributed throughout almost 
all chromosomes without specific hotspots (Wentzensen et al., 2004). However, it has 
been observed that integration may occur also near or within common fragile sites (CFSs) 
(Thorland et al., 2003; Kraus et al., 2008), the genomic regions prone to chromosome 
breaks. Wentzensen et al. reported HPV integration in fragile sites in 38 % of the analyzed 
integration sites of primary tumor samples of anogenital tract, head and neck region, and 
cell lines (Wentzensen et al., 2004). Moreover, the integration of virus into the host 
genome often leads to the disruption or deregulation of the important target genes 
including tumor suppressor genes, to chromosomal rearrangements or to upregulation of 
genes involved in cancer progression (Parfenov et al., 2014; Akagi et al., 2014). 
The integration near known growth-control genes, including frequently targeted MYC 
locus, TP63 or telomerase reverse transcriptase TERT (Wentzensen et al., 2002; 
Ferber et al., 2003; Wentzensen et al., 2004; Peter et al., 2006) located in or near 
translocation breakpoints, or in/near the transcriptionally active regions (Lace et al., 2011; 
Schmitz et al., 2012; Khoury et al., 2013; Bodelon et al., 2016) were detected. These data 
suggest that the elevated expression of the viral oncoproteins is not the only mechanism 
leading to the oncogenesis, but the prompt changes in the host genome due to the 
integration are an alternative way. 
  
2.1.6.3 Epigenetic alterations 
Among other factors that can contribute to the disease progression belong 
epigenetic alterations. During all stages of carcinogenesis, many types of epigenetic 
alterations, including DNA methylation or histone modification, may occur in HPV as 




well as in host genome. These changes, which do not lead to mutations of DNA can cause 
the disease as well. DNA methylation is a covalent chemical modification of cytosine by 
methyltransferase enzyme leading to the formation of 5-methylcytosine and to the 
inactivation of the target gene. Aberrant methylation has been described in a number of 
tumor suppressor genes (TSGs), cell cycle regulators or DNA repair genes in CIN lesions 
and cervical cancer (reviewed in Saavedra et al., 2012). Global DNA hypomethylation in 
cervical neoplastic tissues and its increase over the progression of neoplasm leading to an 
activation of certain proto-oncogenes has been also observed (Kim et al., 1994). 
Furthermore, the altered methylation influencing the malignant transformation has been 
also observed in HPV genome. Kalantari et al. were the first to claim that the methylation 
of the 3´ region of the L1 gene is associated with neoplastic progression (Kalantari et al., 
2004). They detected this region heavily methylated in cervical cancer, however, low 
level of methylation was observed in low-grade lesions. Later, also the methylation of L2 
and E5 genes has been observed in neoplastic lesions (Brandsma et al., 2009).  
As mentioned above, epigenetic alterations may be an alternative mechanism 
through which the expression of the main viral oncoproteins E6 and E7 can be influenced. 
These oncoproteins are negatively regulated by the viral protein E2 which binds to the 
four conserved E2BSs in the LCR rich in the CpG motifs and thus contribute to the 
deregulation of the E6 and E7 expression during disease progression. Methylation of 
these sites leads to the inability to bind the E2 protein and suppression of its regulatory 
function (Kim et al., 2003). Chaiwongkot et al. have revealed in their study on cervical 
lesions that the methylation of E2BSs appears to change during neoplastic progression 
and depends on the integration status of the viral genome (Chaiwongkot et al., 2013). 
Similarly, Reuschenbach et al. (Reuschenbach et al., 2015) have pointed to the 
association of E2BSs methylation with E2 integrity and viral genome status in 
HPV-associated oropharyngeal squamous cell carcinomas, and Sen et al. have shown 
differential molecular signatures among cervical carcinoma cases with episomal and 
integrated HPV16 (Sen et al., 2017). On the other hand, in the study by Bryant et al. 
focusing on samples of vulvar carcinomas, no significant differences in the methylation 
levels based on the viral status were detected (Bryant et al., 2014). The methylation status 
of E2BSs as an alternative mechanism leading to the increase of E6/E7 expression and 
thus cellular transformation in tumors with extrachromosomal form of the virus was also 
studied in our laboratory. Unlike others, increased level of methylation in E2BSs has been 




observed in tonsillar tumors with integrated form of the virus (Pokryvkova et al., 
manuscript in preparation). 
 
2.2 Head and neck cancer 
Head and neck cancer is the ninth most common malignancy in the world with 
more than 500 thousand new cases annually worldwide (Ferlay et al., 2015; Gupta et al., 
2016). The incidence and mortality of HNC depends on gender, cancer sub-site and 
country. Regardless of whether the country is developed or developing, there is an 
increase in both parameters, except for mortality rate in the USA, which has been 
decreasing in last four decades (Gupta et al., 2016). More than 90 % of these tumors are 
characterized as SCC arising from the epithelial cells of the mucosal lining in the head 
and neck regions (e.g. oral cavity, pharynx, and adjacent regions) (Figure 2-6).  
 
Figure 2-6: Illustration of possible head and neck cancer regions (http://cancer.gov). 
 
The differences in the worldwide incidence and mortality is given by the 
variations in the exposure to the main risk factors. Most of the cases are associated with 
smoking and alcohol consumption, both of which increase the mutation rates in important 
cellular pathways (Hashibe et al., 2009; Zygogianni et al., 2011; Gaykalova et al., 2014). 
Approximately 33 % of HNC cases are associated with smoking alone (Hashibe et al., 
2009). Berthiller et al. have demonstrated that already smoking of >0-3 cigarettes per day 
is associated with a 50% increased risk of HNC. However, the duration in smoking plays 
also important role since this increased risk has not been found among smokers with 
smoking duration shorter than 20 years (Berthiller et al., 2016). By contrast to smoking, 




nearly 4 % of HNC is attributed to alcohol consumption alone and nearly 35 % of HNC 
is related to both smoking and alcohol (Hashibe et al., 2009).  
Furthermore, HR-HPV infection is also recognized as another primary cause of 
HNC. The first evidence indicating the relationship between oral carcinogenesis and HPV 
infection was reported by Syrjanen et al. (Syrjanen et al., 1983). The strongest association 
with HPV has been described for oropharyngeal carcinomas, specifically those involving 
tonsils and base of tongue (Nordfors et al., 2014). Contrary to cases related to the tobacco 
use, the incidence rates of oropharyngeal carcinomas associated with HPV is increasing 
(Chaturvedi et al., 2008; Chaturvedi et al., 2013), which fact is influenced by changes in 
sexual behavior; earlier age of sexual debut, higher number of sexual partners or 
insufficient use of barrier protection (Smith et al., 2004; Gillison et al., 2008; Rettig et al., 
2015). However, the proportion of HPV-associated oropharyngeal cancers varies around 
the world. In the USA about 40-80 % of oropharyngeal cases are associated with HPV, 
whereas in Europe the percentages ranges from 90 % in Sweden to less than 20 % in 
countries with the highest rates of tobacco use, namely the Netherlands (23-29 %), France 
(17 %) or Germany (17-63 %) (Nasman et al., 2009; Marur et al., 2010). 
In the Czech Republic, HR-HPV DNA has been detected in 18 % of oral and in 68 % of 
oropharyngeal carcinomas, and the seropositivity of antibodies to HPV E6/E7 
oncoproteins was 56 % in patients with oropharyngeal tumors, which fact further supports 
the etiological association of HR-HPV with tumors of this location (Tachezy et al., 2009). 
The most prevalent HR-HPV type in HNC is HPV16 detected with up to 95 % of 
oropharyngeal cancers followed by HPV33 and HPV18 (Dayyani et al., 2010; 
St Guily et al., 2011; Koslabova et al., 2013).  
Interesting, and clinically important, fact is that patients with HPV-associated 
carcinomas are commonly younger and have significantly better disease-specific and 
overall survival compared to patients with HPV-independent tumors (Hafkamp et al., 
2008; Dayyani et al., 2010; Rotnaglova et al., 2011). Moreover, Jung et al. have also 
revealed in their study that the overall survival of the patients depends on the fact whether 
the virus is transcriptionally active or not (Jung et al., 2010). They claim that 
HPV-negative and HPV DNA-positive/RNA-negative patients show similar survival rate 
whilst tumors with transcriptionally active virus are associated with better prognosis. 
Zhang et al. performed an integrative analysis of genomics and transcriptomics data from 
Cancer Genome Atlas and found that the replication of HPV genome and its invasion into 




the host genome may enhance DNA repair mechanisms since the genes involved in DNA 
mismatch repair pathways were found upregulated in HPV-positive tumors, and as such 
they limit the accumulation of lethal somatic mutations (Zhang et al., 2016). 
The differences in survival should be given also by the diverse immunological responses 
of patients with HPV-positive and HPV-negative tumors. Nevertheless, the underlying 
mechanisms for this prognostic advantage of HPV-related tumors are unclear and further 
studies are needed to clarify this observation.  
The early-stage tumors are mostly treated with one treatment modality such as 
surgery or radiotherapy. The treatment of advanced tumors is usually multimodal 
requiring the combination of surgery with the adjuvant postoperative radiotherapy and/or 
chemotherapy. Regarding the prognostic advantage of patients with HPV-positive HNC 
and their better outcome regardless of the treatment strategy (Licitra et al., 2006), it is 
important to think about the improvement of life of the survivors and eventually 
de-intensify the treatment regimens based on the HPV status or developing of some new 
HPV-specific treatment strategies (Klozar and Tachezy, 2014). Several studies are 
currently testing de-escalation of the treatment in order to reduce the side effects 
(Kimple and Harari, 2014; Mirghani et al., 2015), and the first results can be expected in 
the upcoming years. Besides, unlike cervical cancer which develops from clinically 
well-defined and visible precancerous lesions, oropharyngeal tumors are not usually 
detected in the early stages, most likely due to the locations of the lesions in tonsillar 
crypts and their worse accessibility for diagnosis, and the majority of patients present 
more advanced disease where the radical and mutilating treatment is required. Therefore, 
better understanding of specific molecular mechanisms in HPV-associated tumorigenesis 
and identification of useful and clinically relevant biomarkers of HPV-related tumors will 
provide more opportunities for improvement of diagnostics, target selected pathways 
during the treatment and specify more precisely the prognosis of patients.  
 
2.2.1 Differences in carcinogenesis of HPV-positive and HPV-negative 
HNC 
As mentioned in chapter 2.1.4, HPV encodes two main oncoproteins E6 and E7 
which are the key players in HPV-associated oncogenesis where the main regulators of 
cell cycle are inactivated through their function. The main mechanisms of HPV 
oncoproteins functions are illustrated in the Figure 2-7. On the contrary, in HPV-negative 




tumors, the malignant progression is associated mostly with the mutations of the cellular 
cycle key genes. In HPV-positive tumors, one of the most important cellular tumor 
suppressor p53 is inactivated and degraded by the activity of E6 and thus these tumors 
basically harbor wild-type p53, in contrast to HPV-negative tumors which are 
characterized by genetic alterations of the p53 pathways and show p53 mutations 
occurring in 46-73 % of cases (Riaz et al., 2014). In a great part of HPV-negative tumors, 
the gene CDKN2A encoding the protein p16, is inactivated through homozygous 
deletions, loss of function mutations or epigenetic alterations (Hayes et al., 2015). 
This protein is a cyclin-dependent kinase inhibitor (CDKI) that inhibits pRb 
phosphorylation through the disrupting of cyclin D1/CDK4/6 complex, and thus blocks 
the progression of cell cycle. Its inactivation in HPV-negative tumors is associated with 
the worse prognosis of patients (Namazie et al., 2002). Since the expression of p16 occurs 
because of the inactivation of the pRb, the HPV-positive tumors are characterized by the 
high expression of p16 as a consequence of the pRb inactivation by oncoprotein E7 when 
the transcriptional factor E2F is released and positively regulates the expression of 
CDKN2A. For this reason, the p16 has been denoted as a surrogate marker of active HPV 
infection in cervical tumors (Sano et al., 1998; Cuschieri and Wentzensen, 2008). 
However, it is not sufficient for the determination of active viral infection in 
HPV-positive HNC and it is recommended to use the combination of 
immunohistochemical detection of the p16 and detection of HPV DNA 
(Rotnaglova et al., 2011; Hoffmann et al., 2012) with the consideration of the tumor 
location (Lukešová, 2014). 
 
Figure 2-7: Main mechanisms of HPV-induced oncogenesis (adapted from 
Polanska et al., 2014). 
 
Stransky et al. performed a whole-exome sequencing analysis of head and neck 
tumors of both etiologies and revealed that the mutation rate of HPV-positive tumors was 




approximately half of that found in HPV-negative tumors (Stransky et al., 2011). Another 
large-scale sequencing analysis performed by Agrawal et al. revealed fourfold difference 
in the mutation rate (Agrawal et al., 2011). The discrepancy in the results may arise from 
the bioinformatics technologies or methodological nuances, however, the results of both 
studies are consistent with the notion of biological differences between these two types 
of HNC etiologies.  
The main molecular differences between HPV-positive and HPV-negative head 
and neck tumors and their frequencies are summarized in Table 2-1. In HPV-positive 
tumors, a broad deletion in chromosome 11q has been detected including region of tumor 
suppressor gene ATM participating in DNA repair and control of the progression of cell 
cycle (Hayes et al., 2015). The inactivation of the gene TRAF3 has been revealed in 
approximately 20 % of HPV-positive tumors which is implicated in the immune response 
to the viral infection (Oganesyan et al., 2006). Moreover, this gene is also a component 
of the NF-κB signaling pathway implicated in cell survival (Hacker et al., 2011). 
HPV-associated tumors display the evidence of induction of apoliprotein B mRNA 
editing enzyme catalytic popypeptide-like (APOBEC) family of proteins 
(Henderson et al., 2014). These enzymes catalyze the deamination of cytosine and 
mediates mutations in genes, including proto-oncogene PIK3CA, which plays role in 



















Very common genetic alteration in HPV-negative tumors is an increase of the 
copy number of gene for cyclin D1 (CCND1) and deletion of cyclin-dependent kinase 
inhibitor 2A/B (CDKN2A/B) involved in the cell cycle regulation leading to its 
progression (Lechner et al., 2013; Seiwert et al., 2015). Amplifications of EGFR and 
receptors for fibroblast growth factor (FGFR1) are also predominated in HPV-negative 
tumors (Sok et al., 2006; Cancer Genome Atlas Network, 2015). Their tyrosine kinase 
activity initializes the signaling pathways leading to cell proliferation and tumor 
progression. Another alteration in head and neck tumors is loss-of-function mutations in 
NOTCH1 gene playing role as a tumor suppressor. This leads to amplification of 
transcription factor TP63 regulating cell growth, proliferation or cell adhesion 
(Candi et al., 2007; Agrawal et al., 2011). 
 
2.3 MicroRNA 
MicroRNAs (miRNAs) are a class of short, single-stranded and noncoding RNAs 
with the length ~21 nucleotides that play a very important role in the post-transcriptional 




regulation of gene expression (Bartel, 2004). MiRNAs are involved in many cellular 
processes, such as development, cell growth, differentiation processes, survival, or 
regulation of apoptosis in a variety of eukaryotic organisms, and the deregulated 
expression of miRNAs has been observed in many types of human cancer (Calin et al., 
2002; Ambros, 2004; Bartel, 2004; Lu et al., 2005; He et al., 2005). It is suggested that 
the expression of at least 60 % of human protein-coding genes is regulated by miRNAs 
since they comprise conserved sites for miRNA binding (Friedman et al., 2009).  
The investigation of miRNAs dates back into 1990s, when Victor Ambros with 
his colleagues Rosalind Lee and Rhonda Feinbaum discovered that the gene lin-4 does 
not encode a protein but produces a pair of small RNAs (Lee et al., 1993). Afterwards, 
they showed that these RNAs had antisense complementarity to the multiple sites in the 
3´untranslated region of lin-14 gene, which fact leads to the repression of the lin-14 
expression involved in the development of the Caenorhabditis elegans (Lee et al., 1993; 
Wightman et al., 1993). Several years later, the discovery of let-7 small RNA controlling 
the expression of other genes involved in C. elegans development supported these 
observations (Reinhart et al., 2000). Shortly afterwards in 2001, the term miRNA was 
used at first in several related papers published in Science (Lee and Ambros, 2001; 
Lau et al., 2001; Lagos-Quintana et al., 2001). Since that time, up to 48 885 mature 
miRNA products were identified across 271 species, from that 2 693 mature miRNAs and 
more than 1 984 precursor hairpins have been identified in humans (miRBase 22 launched 
in March 2018, http://mirbase.org).  
 
2.3.1 Biogenesis of miRNAs 
Genes encoding miRNAs are located throughout the whole genome. Most of the 
miRNA genes are noncoding and miRNA is the only product. However, miRNAs genes 
located within the intron or in the untranslated region (UTR) of the gene coding protein, 
and/or within the exon of mRNA-like noncoding RNAs (mlncRNAs) have been also 
found (Rodriguez et al., 2004). MiRNAs are not usually located within the coding exons 
since the excision of the miRNA would lead to the loss of the coding protein transcript. 
MiRNAs are grouped into clusters that include physically adjacent miRNA genes 
transcribed from the same primary miRNA (explained below), and to families, which 
include miRNAs based on the sequence similarities.  




Most of the miRNA families undergo the canonical biogenesis pathway 
converting primary miRNA transcript to the mature miRNA (Figure 2-8). The miRNA 
genes are transcribed mostly by RNA polymerase II (RNAP II) or RNA polymerase III 
(RNAP III) in the nucleus of the cell as a primary miRNA transcript (pri-miRNA) 
(Lee et al., 2004; Borchert et al., 2006). The pri-miRNAs have a stem-loop structure with 
hundreds of nucleotides in length and may contain monocistronic transcript producing 
single miRNA or polycistronic cluster coding two or more miRNAs. The pri-miRNAs 
are typically spliced and have 7´methylguanosine cap on the 5´end and polyA structure 
on the 3´end (Calin et al., 2004). Further, the long pri-miRNA is processed by 
a microprocessor complex including RNAse III family enzyme Drosha and its cofactor 
DiGeorge syndrome critical region 8 protein (DGCR8), which generates 
60 - 70 nucleotides long stem-loop precursor miRNAs (pre-miRNAs). Drosha contains 
two tandem RNAse III domains - RIIIa and RIIIb, and double-stranded RNA-binding 
domain crucial for the processing (Han et al., 2004). The pre-miRNA is then exported out 
of the nucleus to cytoplasm by Exportin 5 (Xpo5), a RanGTP-dependent protein, which 
mediates the export of pre-miRNAs with simultaneous hydrolysis of 
guanosintriphosphate (GTP) bounded on the cofactor Ran (Yi et al., 2003; 
Bohnsack et al., 2004).  
 
Figure 2-8: Canonical miRNA biogenesis pathway (S. Lin and Gregory, 2015). 
 
The second part of the miRNA biogenesis occurs in the cytoplasm. The 
pre-miRNA is further cleaved by the complex composed of RNase III endonuclease 
(DICER1) which leads to transactivation of the RNA-binding protein (TRBP) and 
kinase-R-activating protein (PACT) response generating a mature 20-25 nucleotide long 




miRNA duplex with 2-nucleotide 3´overhangs consisting of a guide strand referred as 
miRNA, and passenger strand referred as miRNA* (Chendrimada et al., 2005; Lee et al., 
2006; Feng et al., 2012). The guide miRNA strand is then bounded to the Argonaute 
proteins 1-4 (Ago 1-4) to form the final RNA-induced silencing complex (miRISC) which 
guide the mature miRNA to their target genes for post-transcriptional regulation. 
The miRNA* strand is typically degraded, however, for some miRNAs, both strands 
generated from the miRNA-miRNA* duplex can be loaded to the miRISC. The strand 
generated from the 5´end of the precursor is then noted as 5p, and the strand from 3´end 
as 3p. Consequently, one miRNA gene produces two different mature miRNAs with 
different targets, and, therefore, different biological functions. The more frequent strand 
loaded into the miRISC depends also on the cell type.  
The Ago 2, mostly found in humans, is supported by the GW182 protein family 
(Gregory et al., 2005; Rehwinkel et al., 2005), and has a RNA cleavage activity, which 
facilitates the seeking of the target mRNA. For the target association, 2-7 nucleotides of 
miRNA known as “seed” region is important (Grimson et al., 2007). Depending on the 
degree of complementarity, the binding of the target gene, which mostly occurs in the 
3´untranslated region, induces the translation inhibition or degradation of the target 
mRNA occurring in the specific cytoplasmic foci called P-bodies containing untranslated 
mRNA (Liu et al., 2005).   
Beside the most common canonical pathway of miRNA biogenesis, some 
alternative pathways have been described. The first one is the case of miRNA genes called 
miRtrons that are encoded within the intronic region of the genes (Ruby et al., 2007; 
Okamura et al., 2007; Berezikov et al., 2007). In this pathway, the step including Drosha 
processing of pri-miRNA into pre-miRNA is bypassed. Instead, the miRtron is spliced by 
the spliceosome and debranching enzymes to generate pre-miRNA. This miRtron-derived 
pre-miRNA is further processed in the same way as in the canonical pathway. Other 
alternative pathway is Dicer-independent where the pre-miRNA is at first classically 
generated by microprocessor complex and exported to the cytoplasm, but later the 
precursor is directly bound by Ago 2 cleaving the star strand and the mature miRNA 
trimmed by 3´-5´exonuclease poly(A)-specific ribonuclease (PARN) is loaded on the 
miRISC (Cifuentes et al., 2010; Cheloufi et al., 2010; Yoda et al., 2013). The combination 
of both-mentioned alternative pathways is used by miRNAs called simtrons 
(splicing-independent miRtron-like miRNAs) whose biogenesis is independent on 




DGCR8, DICER, Xpo5, or Ago proteins. The synthesis of simtrons is reduced only in the 
absence of Drosha (Havens et al., 2012). 
 
2.3.2 Mechanisms of miRNA function 
The mechanism of miRNA function and binding to the target sequences differ in 
animals and plants. With animals, miRNA binds to the mRNA target site with partial base 
pairing which mostly leads to the translational repression with a little or no influence on 
the abundance of mRNA. With plants, miRNAs perfectly base pairs with their targets 
which induces the cleavage and degradation of mRNA. Nevertheless, despite these 
differences in target recognition, there is the evidence that miRNA can induce the mRNA 
degradation in animals through the interaction with additional proteins, and that the 
translational inhibition occurs also in plants, but the underlying mechanisms are not yet 
known (Huntzinger and Izaurralde, 2011). Furthermore, some evidence about 
posttranscriptional activation of translation caused by miRNA function has been 
published in recent years (Ørom et al., 2008). 
In the case of plants, the fully or almost complementary target sites of miRNAs 
are localized in coding exons as well as in 3´ UTR (Jones-Rhoades and Bartel, 2004). 
The cleavage is mediated by PIWI domains of Ago proteins in the miRISC which have 
RNase activity and cleave the target mRNA in the position facing nucleotides 10 and 11 
of the miRNA (Ameres and Zamore, 2013). As for animals, the majority of miRNAs 
forms partial duplexes with the 3´ UTR of their target sequences (Jones-Rhoades and 
Bartel, 2004). However, the interaction with the 5´ UTR has been also identified 
(Ørom et al., 2008). The complementarity is localized in 2-7 nucleotides long region on 
the 5´ end of the miRNA, referred as “seed” region. Such partial complementarity 
prevents the cleavage activity of the miRISC and additional effector proteins for the 
translational repression or mRNA decay are then required (Bartel, 2009). 
 
2.3.2.1 Translational inhibition 
The exact mechanisms of how miRNAs block protein production are still 
intensively studied, but there is an evidence for the inhibition of translational initiation or 
elongation as well as for direct proteolysis of the synthetized peptide. Several factors are 
required for the initiation and the correct continuation of translation (reviewed in 




Jackson et al., 2010). Messenger RNAs competent for the translation have the 5´ cap 
structure and 3´ polyA tail. The cytoplasmic polyA-binding protein (PABP) associated 
with the 3´ polyA interacts with the eukaryotic translation-initiation factor 4G (eIF4G) 
which through 5´ cap-binding protein eIF4E stabilizes the mRNA, protects it from the 
degradation and recruits the pre-initiation complex. Protein GW182, which is the 
component of the miRISC interacts with the PABP and deadenylase complexes 
CCR4-NOT promoting shortening of the polyA tail and dissociation of PABP from the 
target mRNA (Zekri et al., 2009; Zekri et al., 2013). This results in the break of the loop 
structure necessary for the initiation of translation and miRNA-mediated repression of 
the translation. The other mechanism how protein GW182 mediates the translational 
repression is its recruitment of downstream translational repressors such as DEAD-box 
RNA helicase (DDX6) or elongation factor 4E-binding protein 4E-T (Su et al., 2011; 
Kamenska et al., 2014). Mechanisms independent of the GW182 have been also 
demonstrated. It has been shown that miRNAs mediate the dissociation of 
ATP-dependent RNA helicase eIF4A from the cap-binding complex eIF4F which leads 
to the inhibition of ribosome binding and/or ribosomal scanning (Fukao et al., 2014). 
The assumption that the translation might be repressed at the post-initiation stage 
was supported by the evidence that miRNAs and their targets were found associated with 
translating polysomes (Maroney et al., 2006; Nottrott et al., 2006). Nottrott et al. 
suggested that specific proteases or factors recruiting proteases might be associated with 
miRISC leading to the inhibition of nascent polypeptide chain elongation (Nottrott et al., 
2006) whereas Petersen et al. proposed that miRNAs induce ribosome drop off 
(Petersen et al., 2006). The support of the idea that miRNAs regulate translation after its 
initiation has been provided through the observation that repression of translation occurs 
also during translation initiated independently on the cap structure through an internal 
ribosome entry site (IRES) allowing cap-independent association of ribosome with 
mRNA (Petersen et al., 2006). 
In plants, miRNAs were initially thought to mediate the gene silencing only 
through the endonucleolytic activity of Ago proteins since they bind to the fully 
complementary target sequences and they lack GW182 homolog proteins. Although 
several reports suggesting translational repression in addition to cleavage have been 
published (Brodersen et al., 2008; Yang et al., 2012; Li S. et al., 2013), detailed molecular 
roles of participating proteins in plant miRNA pathways still need to be elucidated.   





2.3.2.2 mRNA degradation 
The mRNA degradation is the main mechanism of miRNA-mediated 
posttranscriptional regulation of gene expression in plants. In animal cells, where the 
complementarity between miRNA and target mRNA is only partial, the mechanism exists 
but it is less frequently used. In such regulation, miRNAs direct their targets to the cellular 
5´-to-3´mRNA decay pathway initiated by the removal of the polyA tail by 
CAF1-CCR4-NOT and PAN2-PAN3 deadenylase complexes recruited to the target 
mRNA by GW182 protein through its two conserved motifs (Fabian et al., 2011). Target 
mRNA is then processed by the decapping enzyme DCP2 and its cofactors recruited by 
miRISC (Nishihara et al., 2013), and the decapped mRNA is degraded by the major 
cytoplasmic 5´-to-3´ exonuclease XRN1. This degradation is done in cytoplasmic 
processing granules known as P-bodies which function as the sites for mRNA decay 
because they are enriched for the decapping enzymes and other proteins involved in 
5´-3´degradation (Sheth and Parker, 2003; Cougot et al., 2004). The P-bodies also do not 
contain the ribosomal component and may serve as a mRNA storage without translation 
(Aizer et al., 2014). 
Contrary to animal miRNAs, plants miRNAs do not undergo deadenylation but 
they direct the endonucleolytic target mRNA cleavage through action of Ago proteins 
(Ameres and Zamore, 2013). Afterwards, the 3´ end of 5´-cleaved fragments are 
uridylated by terminal uridylyl transferases (TUTases) and are accumulated in P-bodies 
(Xu et al., 2016). After the decapping, the 5´-cleaved fragments might be degraded in 
5´-3´ decay through the exonucleases XRN or in 3´-5´ decay through exonucleolytic 
complex called exosome (reviewed in Souret et al., 2004; Eulalio et al., 2007). 
The 3´-cleaved fragments resulting from the endonucleolytic cleavage contain 
a 5´-monophosphate (instead of 5´cap) and are degraded also by the 5´-3´exonuclease 
XRN4. 
 
2.3.2.3 Translational activation 
Although the function of most miRNAs has negative effect on the mRNA 
translation, the positive regulation of translation has been also observed. Vasudevan et al. 
revealed in their study that miR-369-3 directs the Ago protein and fragile X mental 




retardation-related protein 1 (FXR1) to the AU-rich elements (AREs) of the tumor 
necrosis factor α (TNFα) and thus activate the translation (Vasudevan et al., 2007). 
Moreover, Ørom et al. reported an association of miR-10a with the 5´untranslated region 
of mRNA encoding ribosomal proteins which enhanced their expression (Ørom et al., 
2008). However, despite such evidence, the miRNA-associated activation of mRNA 
translation is poorly understood. 
 
2.3.3 miRNA and cancer 
Cancer is a condition of cells with abnormal growth and deregulated expression 
of genes, including miRNAs. MiRNAs influence many steps in tumor development, such 
as tumor growth, invasion, angiogenesis or formation of metastasis.   
The evidence of the role of miRNAs in human tumors was at first reported in 2002 
by Calin et al. (Calin et al., 2002), who studied a region on chromosome 13q14, 
frequently found deleted in B cell chronic lymphocytic leukemias (B-CLL). 
They reported that this region contains two polycistronic miRNA genes, miR-15 and 
miR-16, and showed that the deletion of this region correlates with the downregulation 
of these miRNAs expression. Following this study, they mapped 186 miRNAs and 
showed that miRNA genes are frequently located in cancer-associated genomic regions 
or in fragile sites (Calin et al., 2004), and they first provided a list of miRNA genes that 
may play role in cancer.  
The fact that miRNAs posttranscriptional regulate gene expression implies their 
dual role in tumors. First, miRNA genes which are often amplified in tumors negatively, 
regulate the expression of crucial tumor suppressors genes and thus mediate tumor 
progression. These miRNAs are commonly denoted as oncomiRs. On the other hand, 
miRNAs normally maintain the right function of cell cycle progression and negatively 
regulate oncogene expression. These miRNA genes are frequently located in fragile sites 
and are often deleted or mutated in tumor cells.  
Contrary to mRNA profiles, it has been shown that tumors as well as normal 
tissues of different origin have specific miRNA expression signatures called miRNome 
(Lu et al., 2005; Volinia et al., 2006). This fact of uniqueness provides to miRNAs a great 
potential to be useful biomarkers for diagnosis of cancer. Furthermore, specific miRNA 
profiles allow to distinguish between different tumor subtypes, for example, in human 




breast cancer (Blenkiron et al., 2007), in non-small-cell lung carcinoma (Lebanony et al., 
2009), or in ovarian cancer (Iorio et al., 2007).               
 
2.3.3.1 Mechanisms of miRNA deregulation in cancer 
During the recent years, the underlying mechanisms of miRNA deregulation in 
cancer have become clearer, including structural genetic alterations, transcriptional 
control changes, epigenetic regulation and/or defects in miRNA biogenesis machinery.  
The aberrant miRNA expression in tumors is often caused by chromosomal 
abnormalities of miRNA genes such as amplifications, deletions or translocations. As 
mentioned above. Calin et al. showed that more than half of miRNA genes are located in 
genomic regions that are altered in cancer (breakpoint regions and fragile sites, amplified 
regions, common sites for translocation, deletion or viral integration) (Calin et al., 2004; 
reviewed in Calin and Croce 2006). High proportion of DNA copy number alterations 
was determined also by Zhang et al. in ovarian cancer, breast cancer and melanoma 
(Zhang et al., 2006). Although the point mutations or single nucleotide polymorphisms 
(SNP) in miRNA coding genes have been detected at very low level (Saunders et al., 
2007), several studies have indicated that these events may cause the deregulation of 
miRNA expression, for example in prostate (Xu et al., 2010) or breast cancer (Li et al., 
2009). 
Other mechanism of miRNA expression deregulation is mediated by transcription 
factors activity, such as c-Myc or p53. O´Donnell et al. revealed that c-Myc activates the 
expression of the oncogenic cluster miR-17-92 and thus regulates the cell proliferation 
and apoptosis (O'Donnell et al., 2005). Later, the same group revealed the widespread 
downregulation of tumor suppressive miRNA expression, such as miR-15a, miR-26, 
miR-29, miR-30 or let-7 family, induced by oncogenic c-Myc (Chang T.C. et al., 2008). 
Other example of c-Myc function is the regulation of tumor suppressive miR-122 whose 
disruption results in development of hepatocellular carcinoma (Wang B. et al., 2014). 
Contrary to c-Myc, transcription factor p53 has tumor suppressive role. The most 
significant miRNA family regulated by this protein is mir-34, which promotes cell cycle 
arrest, cell senescence and apoptosis (He et al., 2007; Hermeking, 2010). Other studies 
described additional miRNAs regulated by p53, such as miR-107, miR-200, miR-192 or 
miR-605 regulating angiogenesis, epithelial-to-mesenchymal transition (EMT) and/or 
expression of ligase MDM2 (Yamakuchi et al., 2010; Pichiorri et al., 2010; Chang et al., 




2011; Xiao et al., 2011). Since p53 is often lost or mutated in cancer, miR-34 and other 
miRNAs regulated by this protein are frequently downregulated in tumor cells.  
Just as protein coding genes, miRNA coding genes are regulated also by 
epigenetic modifications, such as DNA methylation or histone acetylation. 
Hypermethylation of CpG islands in promotors is one of the most common cause of the 
loss of tumor suppressive miRNA expression leading to the development of cancer 
(reviewed in Lopez-Serra and Esteller, 2012). For an example, Fazi et al. revealed that 
fusion protein AML1/ETO triggers heterochromatic silencing of miR-223 expression by 
CpG methylation (Fazi et al., 2007). Saito et al. showed increased expression of several 
miRNAs after treatment of bladder cancer cells with chromatin modifying inhibitors 
(Saito et al., 2006). Further, Scott and his colleagues revealed rapid alteration of miRNA 
levels followed histone deacetylase inhibition in breast carcinoma cells (Scott et al., 
2006). Overall, using epigenetic drugs offers the possibility to restore the expression of 
tumor suppressive miRNAs and, through this process, to treat the tumor.  
As mentioned above, the biogenesis pathway of miRNAs is a multistep process 
including many regulating proteins and enzymes. Therefore, mutations or aberrant 
expression of these components could lead to changes in miRNA expression and thus 
contribute to tumor development. The key RNase III endonucleases Drosha and DICER 
have been found deregulated in tumors. Walz et al. reported mutations of Drosha and its 
cofactor DGCR8 in 15 % of Favorable Histology Wilms Tumors (FHWT) leading to 
significant decrease in expression of mature let-7a and mir-200 family (Walz et al., 2015). 
The endonuclease DICER was found upregulated in 81 % of prostate adenocarcinoma 
leading to global increase of miRNA expression (Chiosea et al., 2006), in precursor 
lesions of lung adenocarcinoma (Chiosea et al., 2007) and was significantly associated 
with aggressive form of breast cancer (Caffrey et al., 2013). On the other hand, 
Karube et al. revealed reduced expression of DICER in lung tumors associated with poor 
prognosis (Karube et al., 2005). Other essential components of miRNA biogenesis 
machinery are Ago proteins. Zhang et al. published a study revealing upregulated Ago2 
expression in gastric cancer (Zhang et al., 2013), contrary to Völler et al. who identified 
downregulation of Ago2 expression in melanoma (Voller et al., 2013). Further, export of 
miRNAs from nucleus to cytoplasm is provided by XPO5 which was found mutated in a 
subset of human tumors with microsatellite instability (Melo et al., 2010). This genetic 
defect traps pre-miRNAs in the nucleus and avoids the miRNA inhibiting function. 




2.3.3.2 MiRNAs as biomarkers in clinical management of cancer 
There is number of characteristics explaining the meaning of the word biomarker 
as a shortcut for biological marker. The Biomarkers Definition Working Group convened 
by National Institute of Health (NIH) defined a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Biomarkers Definitions Working Group, 2001). In terms of cancer research there is an 
effort to identify useful and reliable biomarkers to provide diagnostic, prognostic and 
therapeutic information. Several biomarkers are nowadays widely used in clinical 
practice, such as prostate-specific antigen (PSA) for prostate cancer, human epidermal 
growth factor receptor 2 (HER2) for breast cancer or α-fetoprotein (AFP) for liver cancer. 
Nevertheless, there is still a need for biomarkers that could detect early stages of cancer 
and, based on their presence/absence the individual treatment, could be applied and/or the 
prognosis of patient´s could be predicted.  
As mentioned above, miRNA expression profiles are specific for tumors of 
different origin, therefore, they have a potential to be useful and sensitive biomarkers. 
Moreover, due to their small size, miRNAs are more stable than other molecules like long 
mRNAs (Jung et al., 2010) and are less prone to degradation caused by processing and 
storage conditions.   
First, miRNAs as biomarkers are usable in connection with the precise diagnosis 
of the primary tumor site since it improves the patients´ outcome and reduces the 
treatment costs. For example, Feraccin et al. performed the study using miRNA profiling 
as a tool for identification of cancer with unknown primary tissue-of-origin from 
metastases (Ferracin et al., 2011). Overall, they reached 100% accuracy for primary 
cancers and 78% for metastasis. Selection of better treatment strategy can be also based 
on the precise determination of tumor subtype specified by miRNA profiles. Several 
studies on breast cancer (Blenkiron et al., 2007), ovarian cancer (Iorio et al., 2007), renal 
cancer (Youssef et al., 2011) or lung cancer (Gilad et al., 2012) have been published 
distinguishing tumor subtypes by miRNAs expression pattern. Furthermore, the patients´ 
survival and prognosis depends on the stage of tumor at the time of diagnosis which is 
possible to determinate by profiling of miRNA expression. Du Rieu et al. performed 
a study indicating that overexpression of miR-21 and miR-205 precedes the phenotypic 
changes in the pancreatic ducts, which suggests they could function as biomarkers for the 




early diagnosis of pancreatic ductal adenocarcinoma (du Rieu et al., 2010). In addition, 
miRNAs can serve as biomarkers for prediction of patients´ prognosis. For example, 
Hui et al. processed data from The Cancer Genome Atlas database (TCGA) and identified 
miRNAs potentially associated with survival of patients with head and neck cancer 
(Hui et al., 2016). Finally, miRNA signatures serve also as predictors of the response to 
the tumor treatment allowing for timely modifications of the treatment (Giovannetti et al., 
2010; Xu et al., 2014). 
Besides their presence in solid tumors, miRNAs have been also found and isolated 
from body fluids such as blood, plasma, serum, saliva, urine, and other, or circulating 
exosomes (Mitchell et al., 2008; Taylor and Gercel-Taylor, 2008; Michael et al., 2010; 
Hanke et al., 2010; Wang J. et al., 2014) and they are called circulating miRNAs. 
In this extracellular environment, miRNAs are associated with RNA-binding proteins 
such as argonaute proteins, ribosomal proteins, or lipoprotein particles, which protect 
them from nucleases (Turchinovich et al., 2011; Arroyo et al., 2011; Vickers et al., 2011; 
Ashby et al., 2014). Moreover, miRNAs can be transported in the endosome-derived 
extracellular vesicles called exosomes (Valadi et al., 2007). Since it has been observed 
that the alteration of miRNA expression in tumors is reflected also in miRNA profiles 
from exosomes, exosomal miRNAs, as well as other circulating miRNAs, seems to be 
suitable candidates for non-invasive cancer biomarkers (Taylor and Gercel-Taylor, 2008; 
Schwarzenbach, 2015). Nevertheless, the methods for isolation of circulating miRNAs 
are still challenging since there is a low level of miRNA fraction in body fluids and it is 
difficult to separate the exosomes with miRNAs from the rest of other extracellular 
vesicles. Further, in study of Chevillet et al., the most abundant exosomal miRNAs were 
present on average in less than one copy per exosome (Chevillet et al., 2014). Thus, the 
improvement and validation of extraction methods of circulating miRNAs is current hot 
topic of biomarkers´ research.  
 
2.3.3.3 MiRNA profiling studies 
MiRNA profiling is based on the measurement of the relative abundance of 
miRNA expression specific for different species, biological origin or the current state of 
cells. Nowadays, the main methods for miRNA profiling include reverse transcription 
quantitative real-time PCR (RT-qPCR) based approaches, microarrays, next-generation 
sequencing (NGS) based platforms, and/or others (reviewed in Pritchard et al., 2012; 




Chugh and Dittmer, 2012; Tian et al., 2015). Each of these methods has its advantages, 
disadvantages, and limitations, and is suitable for different applications (Mestdagh et al., 
2014). One of the important factors influencing the outcome of the miRNA profiling 
studies is the type of analyzed material; cell lines, fresh frozen (FF) tissues, and 
formalin-fixed paraffin-embedded (FFPE) tissues, blood or other body fluids. Besides the 
material preparation, very important for miRNA expression studies is the data analysis, 
for which there exist a whole range of software programs and different statistical 
approaches.  
The global miRNA profiling of cancers has been extensively studied in clinical 
samples as well as in cancer cell lines. The aim is to uncover the changes occurring during 
tumor development and to increase the knowledge about gene regulation of particular 
disease. However, the published profiling studies are often inconsistent due to the 
different methodological and data analysis approaches, character of samples or etiology 
of the studied tumors, and thus, it is difficult to make some precise, unique and usable 
conclusion about the miRNA gene regulation of the disease. It is, therefore, necessary to 
standardize all steps in the miRNA profiling processes.    
In my thesis, I focus on cervical cancer and head and neck cancer as two types of 
tumors, both etiologically linked to HPV infection - cervical cancer in almost 100 % of 
cases, in the case of HNC, in our previous study, HPV infection was associated with more 
than 60 % of oropharyngeal carcinomas (Tachezy et al., 2009). Thus, these tumors serve 
as unique model for the study of cancer of the same anatomical location caused by 
different molecular mechanisms. Several studies focused on miRNA profiling of these 
tumors have been published recently (Hui et al., 2010; Pereira et al., 2010; Lajer et al., 
2012; Wang X. et al., 2014), however, these lack the information about the etiology of 
the studied tumors. The published miRNA profiling studies of cervical cancer and HNC 
are discussed in more details in chapter 6.  
 
2.3.3.4 HPV-encoded miRNAs 
During tumor development and progression, the host´s miRNA expression is 
altered. Furthermore, several viruses contributing to the oncogenesis encode their own 
miRNAs whose expression might influence the cellular mechanisms as well as viral life 
cycle. Unlike HPV, several groups of human oncoviruses encode their viral specific 
miRNAs (Epstein-Barr Virus, human herpesvirus 8, Merkel Cell Polyomavirus, or 




hepatitis C virus). Two research groups have suggested the existence of HPV-encoded 
miRNAs (Qian et al., 2013; Weng et al., 2017). First, Qian et al. have validated four 
miRNAs and predicted their target genes suggesting their role in cell cycle regulation, 
cell adhesion and migration, or development of cancer (Qian et al., 2013). Several years 
later they detected their expression in cervical samples at very low level (Virtanen et al., 
2016). Recently, Weng et al. have developed genome-wide sequence analyses and 
predicted other HPV-encoded miRNAs by bioinformatics approaches (Weng et al., 
2017). However, no studies of in vivo function of these miRNAs have been published yet. 
This research area is still unexplored and additional investigation is needed.  
 
2.3.4 MiRNAs for clinical use 
As mentioned above, because of their characteristics miRNAs may serve as 
suitable biomarkers for many biological conditions and have a potential to be used not 
only for diagnostics but also as a tool for therapy. There are three therapeutic approaches 
usable for the main required outcomes - the sequestration of upregulated miRNAs by 
artificial miRNA-binding sites, the inhibition of oncogenic miRNAs by small molecules, 
or by chemically modified oligonucleotides (Figure 2-9). The first approach utilizes 
specific miRNA constructs called miRNA sponges (Ebert et al., 2007; Ebert and Sharp, 
2010) (Figure 2-9a) containing multiple artificial complementary sequences or binding 
sites which after the introduction into cells prevent the interaction of nature endogenous 
miRNAs. The typical miRNA sponge contains 4-10 miRNA binding sites. The second 
method is the use of synthetic oligonucleotides complementary to endogenous miRNAs, 
the so-called as antisense oligonucleotides, antagomiRs or anti-miRs which bind miRNAs 
and block their regulatory function (Figure 2-9b) (Krutzfeldt et al., 2005; Krutzfeldt et al., 
2007). Further, the synthetic oligos function also as miRNA mimic when they substitute 
the mature downregulated miRNA and bind its targets. Since these oligonucleotides are 
very unstable, they need to be chemically modified, for example by adding of 
2´-O-methyl or -methoxyethyl groups on ribose or phosphorothioate modifications which 
increase their resistance to cellular nucleases. The third approach is the application of 
small molecules that inhibit or influence various steps of miRNA biogenesis or expression 
and the mature miRNA is thus functionally incompetent (Velagapudi et al., 2014) 
(Figure 2-9c). Important question of this research field is the delivery of therapeutics into 
the cell which can be based on viral transfer or non-viral strategy using polymer-based 




nanoparticles or liposomes (Ben-Shushan et al., 2014; Wang et al., 2015). However, all 
of these strategies have some limitations, such as the reaction of immune system to the 
antagomiRs, occurrence of toxic manifestation, effectivity of the therapeutic delivery or 
assurance of sufficient absorption of the therapeutics into target cells.   
 
Figure 2-9: Main therapeutic strategies based on miRNAs (Li and Rana, 2014). 
 
Despite these difficulties, the therapeutics based on antisense oligonucleotides are 
tested in preclinical and clinical trials. Only one miRNA therapeutic called Miravirsen 
entered clinical trial phase II (Janssen et al., 2013). It is locked nucleic acid-modified 
(LNA-modified) antisense inhibitor of miR-122, which is liver-specific miRNA playing 
role in Hepatitis C Virus (HCV) infection (Gebert et al., 2014). Another therapeutic in 
clinical trial is MRX34 functioning as a delivery system for miR-34 mimic and 
substituting the function of this tumor suppressor miRNA (Beg et al., 2017). 
This therapeutic may be used in variety of tumors. However, the phase I of clinical trial 
was put to halt in 2016 because of serious immune responses (ClinicalTrials.gov; NCT 
number NCT01829971).  




3. AIMS OF THE THESIS 
The thesis focuses primarily on the analysis of miRNA expression in 
HPV-associated and HPV-independent head and neck tumors as a unique model of 
carcinomas with viral and non-viral etiology. The content of the submitted doctoral thesis 
is a result of many years research on human papillomaviruses performed by the group led 
by RNDr. Ruth Tachezy, Ph.D., now working in the Laboratory of Molecular and Tumor 
Virology in BIOCEV in Vestec. The laboratory closely cooperates with clinical 
departments, mainly those in Motol University Hospital, Prague, which allows for 
broadening of the studies and inclusion of clinical samples as well.  
When I joined the laboratory as a doctoral student, the research of miRNAs was 
at its beginning without much experience in this field. The research had been supported 
by the grant from Czech Science Foundation (GACR) in 2012-2015, together with the 
grant supported by Charles University (GAUK) in 2014-2015, on which I participated as 
the principal researcher.  
The main objectives of the thesis were postulated as follows: 
 




4. MATERIAL AND METHODS 
The project was realized in cooperation with several clinical departments, namely 
Department of Otolaryngology and Head and Neck Surgery, 1st Medical Faculty Charles 
University and Motol University Hospital in Prague, and Department of Obstetrics and 
Gynecology, 2nd Medical Faculty Charles University and Motol University Hospital in 
Prague, both of which provided the clinical samples of tonsillar and cervical tumors and 
also healthy tissues. The primary and immortalized human keratinocyte clones were 
provided in cooperation with the University of Iowa, Iowa City, USA. The rest of the 
material was provided by the archives of Department of Experimental Virology in the 
Institute of Hematology and Blood Transfusion, Prague, which also provided most of the 
instrumental equipment. Moreover, we also cooperated with the Institute of Pathological 
Physiology, 1st Medical Faculty Charles University, Prague, with the International 
Agency for Research on Cancer in Lyon in France, which gave us the opportunity to use 
their equipment for miRNA expression analysis, and with the Ruđer Bošković Institute 
in Zagreb in Croatia.   
 





5.1 List of publications related to the thesis 
 
Analysis of the integration of human papillomaviruses in head and neck tumours in 
relation to patients´ prognosis 
Zuzana Vojtechova, Ivan Sabol, Martina Salakova, Lubomir Turek, Marek Grega, Jana 
Smahelova, Ondrej Vencalek, Eva Lukesova, Jan Klozar and Ruth Tachezy 
Int J Cancer. 2016 Jan 15;138(2):386-95. doi: 10.1002/ijc.29712. 
IF2016 6.513 
In this study we focused on detailed characterization of the physical status of 
human papillomaviruses in a set of virus-associated tonsillar tumors, cervical carcinomas 
and clinically unaffected cervical tissues. Using the method based on the mapping of E2 
integration breakpoint, APOT assay, and Southern blot, we determined the percentage of 
samples with integrated viral genome and with extrachromosomal form of the virus. 
Furthermore, we determined the type and the exact site of integration. Finally, we 
performed the survival analysis and revealed which factors influenced the disease specific 
survival and if it is affected also by the physical status of the viral genome in the cells. 
It represents one of the few projects studying the process of integration in the samples of 
head and neck tumors and, till then, it was the first study reporting the lack of influence 
of HPV integration status in head and neck cancer on disease specific survival of patients.  
 
Contribution of the author: 60 %. I processed all samples and performed mapping of E2 
integration breakpoint and APOT assay. Further, I carried out the evaluation of obtained 










Comparison of the miRNA profiles in HPV-positive and HPV-negative tonsillar 
tumors and a model system of human keratinocyte clones 
Zuzana Vojtechova, Ivan Sabol, Martina Salakova, Jana Smahelova, Jiri Zavadil, 
Lubomir Turek, Marek Grega, Jan Klozar, Bohumir Prochazka and Ruth Tachezy 
BMC Cancer. 2016 Jul 4;16:382. doi: 10.1186/s12885-016-2430-y. 
IF2016 3.288 
In this study we performed TLDA analysis to determine the miRNA expression 
profiles in HPV-associated and -independent tonsillar tumors together with 
non-malignant tissues and cervical carcinomas. Further, the miRNA expression profiles 
were evaluated also in primary and immortalized human keratinocyte clones as a model 
system and compared with the clinical samples. We defined miRNAs differentially 
expressed in each group of samples and identified “HPV core” miRNAs specific for only 
HPV-associated tumors. Finally, we determined several miRNAs as potential prognostic 
markers for patients with tonsillar tumors. Overall, our results contribute to the 
identification of useful and clinically relevant biomarkers of head and neck tumors with 
viral and non-viral etiology. 
 
Contribution of the author: 60 %. I processed and characterized all samples and performed 
the TLDA analysis. Further, I contributed to the data analysis, performed the technical 
validation and confirmation of the data. Finally, I prepared the manuscript.  
 
 
Comparison of the miRNA expression profiles in fresh frozen and formalin-fixed 
paraffin-embedded tonsillar tumors 
Zuzana Vojtechova, Jiri Zavadil, Jan Klozar, Marek Grega, Ruth Tachezy 
PLoS One. 2017 Jun 23;12(6):e0179645. doi: 10.1371/journal.pone.0179645. 
IF2017 2.806 
In this study we performed the comparison of the miRNA expression profiles 
between FF and macrodissected FFPE tonsillar tumors using TLDA analysis. Further, we 
analyzed the influence of the used normalization method and software program on the 
results. We observed low overlap of differentially expressed miRNAs between the two 




types of material and the appreciable variation between results evaluated by two types of 
normalization methods. Our study highlights the importance of using the same type of 
clinical material for the comparison of the miRNA expression profiles from published 
studies, and testing and selecting the best-performing normalization method for data 
analysis.  
 
Contribution of the author: 80 %. I contributed to the design of the study, processed the 
samples and performed the TLDA analysis. Further, I analyzed the data and confirmed 
the results. Finally, I wrote the manuscript.  
 
 
The role of miRNAs in virus-mediated oncogenesis 
Zuzana Vojtechova and Ruth Tachezy 
Int J Mol Sci. 2018 Apr 17;19(4). doi: 10.3390/ijms19041217. 
IF2016 3.226 
The review focuses on the oncogenic viruses and summarizes the role of 
virus-encoded miRNAs by which viruses regulate their own expression or influence the 
host gene expression and thus contribute to carcinogenic processes. Further, it deals with 
the role of host´s miRNAs whose expression contribute to the regulation of tumor 
development. The review also discusses the question of miRNAs in some groups of 
oncoviruses, including HPV, where the existence of virus-encoded miRNAs is still 
controversial.  
 
Contribution of the author: 80 %. I contributed to the layout of the review, prepared the 
original draft of the manuscript and edited the final version. 
      
                                                                                                                                                                                     
………….………………………………… 
RNDr. Ruth Tachezy, Ph.D., the supervisor 
 




5.2 List of publications unrelated to the thesis 
 
Detection of human polyomaviruses MCPyV, HPyV6, and HPyV7 in malignant and 
non-malignant tonsillar tissues 
Martina Saláková, Eva Košlabová, Zuzana Vojtěchová, Ruth Tachezy, and Vojtěch 
Šroller 
J Med Virol. 2016 Apr;88(4):695-702. doi: 10.1002/jmv.24385. 
IF2016 1.935 
 
Morphological and proteomic analysis of early stage air-liquid interface biofilm 
formation in Mycobacterium smegmatis 
Zuzana Sochorová, Denisa Petráčková, Barbora Sitařová, Karolína Buriánková, Silvia 
Bezoušková, Oldřich Benada, Olga Kofroňová, Jiří Janeček, Petr Halada, Jaroslav Weiser 
Microbiology. 2014 Jul;160(Pt 7):1346-56. doi: 10.1099/mic.0.076174-0. 
IF2014 2.557 





The thesis focuses on the miRNA analysis in HPV-associated and 
HPV-independent tumors. HPVs are related to almost 30 % of tumors associated with 
infectious agent (Plummer et al., 2016). The most common HPV-associated tumor is 
cervical carcinoma, which is linked to the viral infection in almost 100 %. Among others 
HPV-related tumors are those developed in anogenital region, such as vaginal, vulvar, 
anal, or penile tumors, in which HPV-associated proportion varies between 25-90 % 
(de Martel et al., 2017). HPV is also etiologically linked to the development of head and 
neck tumors, which make from 20 to 90 % depending on the geographical location. 
In my research I focused on the study of tonsillar tumors with double etiology, and 
cervical carcinomas as the most common HPV-related tumors. 
The work started with a very detailed characterization of the samples, including 
not only the detection and typing of HPV DNA and detection of active infection, but also 
the determination of the status of the viral genome. The results of the analysis of 
integration of HPVs was published in 2016 in the International Journal of Cancer 
(Vojtechova et al., 2016). There are several methodological approaches which might be 
used for the analysis of HPV genome status. We chose three different methods for our 
analysis - the mapping of E2 integration breakpoint using a set of specific primers to 
detect short reverse transcript amplicons that could be also used for more fragmented 
samples such as FFPE samples; a very sensitive and specific 3´-RACE-based (Rapid 
Amplification of cDNA Ends) method called APOT assay allowing us to analyze the 
exact site of integration, to identify the structure of HPV transcripts, and also, to detect 
the transcripts derived from both extrachromosomal and integrated genomes in the same 
sample, as well as in the excess of the extrachromosomal HPV copies (Klaes et al., 1999; 
Vinokurova et al., 2008); and finally the Southern blot, a standard method which allows 
detection of the samples with multiple tandem repeats of the viral genome (Lace et al., 
2011).  
Until that time, limited information about HPV integration in HNC had been 
available. Several studies of integration of HPV in HNC (Koskinen et al., 2003; 
Smeets et al., 2006; Lace et al., 2011; Deng et al., 2013; Olthof et al., 2014; Gao et al., 
2014) indicated that around 50 % of HPV-16 positive HNC samples contain integrated 
HPV genome. Our study brought a complex view of HPV integration analyzed with 




different methods and on two types of HPV-associated tumors - tonsillar and cervical, as 
well as with two types of clinical material - FF and FFPE samples. For the analysis of FF 
samples we used all three chosen methods and, based on the most sensitive 
method - APOT assay, we revealed the HPV integration in 36 % of tonsillar tumors, the 
extrachromosomal form of the virus in 43 % of samples and both forms in 14 % of 
samples, which results agree with the data published previously (Koskinen et al., 2003; 
Mooren et al., 2013; Olthof et al., 2014; Gao et al., 2014), although, there are some 
studies revealing the integrated form in more than 60 % of HNC tumors (Hafkamp et al., 
2008; Lace et al., 2011; Khoury et al., 2013). The analysis performed on FFPE samples 
revealed the integrated form of the virus in 27 % of HNC samples. Due to the worse 
quality of isolated RNA from FFPE samples, APOT assay is not applicable for the 
analysis of genome status in this type of material, thus we used only the mapping of E2 
integration breakpoint. This method does not distinguish between the mixed form of the 
virus and it may explain the different percentage of the integrated form detected in this 
way. The comparison of the status of the viral genome as revealed by E2 mapping on 
paired fresh frozen and FFPE samples showed 79% concordance between these two types 
of the material. It is important to note that the differences can be also explained by the 
fact that the samples from the two types of the material will never be exactly the same 
piece of the tumor and that the process of fixation of FFPE samples influences the 
compactness of extracted RNA. In the case of cervical carcinomas in our study, 60 % of 
samples harbored integrated form of virus and the HPV-positive clinically unaffected 
cervical tissues contained integrated virus in 50 % of samples.  
The APOT assay also provided the opportunity to determine the type of 
integration (Lace et al., 2011). In all tonsillar samples with integrated HPV genome we 
detected type A transcripts - spliced from splice donor (SD) 880 to the cellular splice 
acceptor (SA) site. In cervical samples we detected also the type B transcript which is 
spliced from SD 880 to viral SA 3358 and continued to the cellular sequence after 
nucleotide position 3496. Our results confirm the majority of the type A of integrated 
HPV, as published by Lace et al. in keratinocyte clones and tumors (Lace et al., 2011). 
The integration occurred on different human chromosomes without obvious 
predilection. Nevertheless, we identified some integration sites previously detected in 
cervical carcinomas, such as 17q23.1, 3p26.2, or 20p12.1 (Schmitz et al., 2012), where 
the genes encoded in these loci play role in oncogenesis or gene silencing (Wieser, 2007; 




Chen et al., 2011). Similarly to other studies (Smeets et al., 2006; Lace et al., 2011) 
we identified the integration in loci 13q14 and 5q35. The integration in locus 3q28 
encoding protein TP63 was detected in agreement with others (Khoury et al., 2013; 
Olthof et al., 2014). Moreover, in five samples HPV was integrated in the proximity of 
a common fragile sites that were previously presented as affected in cervical carcinomas 
and other solid tumors (Ragin et al., 2004; Lagana et al., 2010). Altogether, we have 
shown that for the oncogenesis initiated by HPVs, not only expression of viral 
oncoproteins, but also other changes in host genome raising from the viral integration are 
needed.  
Our study was the first to report the influence of HPV genome status in HNC on 
disease specific survival (DSS) of patients. We analyzed a set of 186 samples where the 
HPV status was revealed by mapping of E2 integration breakpoint. We confirmed the 
HPV positivity as the strongest prognostic factor for patients with HNC, as published 
previously (Dahlstrand et al., 2008; Rotnaglova et al., 2011). However, our results show 
no statistically significant difference in DSS between patients with integrated form of the 
virus or the extrachromosomal/mixed one, but the patients with the 
extrachromosomal/mixed form of virus seem to have better prognosis and tend to live 
longer without disease recurrence. Similar results were previously published for patients 
with cervical carcinomas by Shin et al. (Shin et al., 2014) who have revealed the HPV 
integration as a poor prognostic factor, and, further, Nambaru et al. (Nambaru et al., 2009) 
have shown better disease-free survival for cervical carcinoma patients with 
extrachromosomal form of virus, however their results were not statistically significant. 
Recently, Nulton et al. have published a study based on TCGA data of 56 samples of 
HNC which revealed worse overall survival of patients with integrated form of HPV 
compared to those with extrachromosomal form (Nulton et al., 2018). 
Until now, there are not many published studies focusing on the differences in 
molecular profiles of HPV-associated and -independent tumors. For the proper 
understanding of mechanisms leading to the tumor development it is appropriate to 
determine whether the changes in molecular profiles are influenced by the presence of 
the virus or by the character of the cells in the region of the tumor development. In 2015, 
The Cancer Genome Atlas network published a study revealing the differences in 
molecular alterations between HPV-positive and HPV-negative head and neck squamous 
cell carcinomas (HNSCC) (Cancer Genome Atlas Network, 2015). Koncar et al. have 




revealed similar molecular profiles in the set of HPV-positive tumors of vulva, anus, 
cervix, and oropharynx (Koncar et al., 2017). Contrary, Tuna and Amos have detected 
similar changes in the genome of patients with HPV-associated tumors with the 
epigenomic and transcriptomic profiles differing between HPV-positive 
and HPV-negative tumors (Tuna and Amos, 2017). These data indicate that the accurate 
and precise determination of the etiology of the disease is necessary for the choice of the 
most appropriate and most effective medication leading to the more personalized 
treatment and prognostic advantage of the patients. Moreover, since the lesions of 
oropharyngeal tumors are most likely located in the tonsillar crypts, these tumors are often 
revealed in the late stage of the disease and the prognosis of patients is thus worse. The 
opportunity how to improve the patients´ prognosis is to find some specific, sensitive and 
clinically relevant biomarker for the earlier and precise diagnostic of the disease. Such 
biomarkers may be miRNAs whose signatures differ between cancer and clinically 
unaffected tissues, and their expression is specific for tumors of different origin. 
In the paper published in 2016 in BMC Cancer (Vojtechova et al., 2016) we 
focused on the evaluation of the miRNA profiles in tonsillar tumors of viral and non-viral 
etiology. Until that time, several studies analyzing miRNA profiles in HNC cell lines 
(Tran et al., 2007; Chang S.S. et al., 2008) and tumors (Childs et al., 2009; Avissar et al., 
2009; Ramdas et al., 2009; Hui et al., 2010) have been published, however, these lacked 
comparability, due to the anatomical heterogeneity of the analyzed tumors, and due to the 
different methodological approaches. Furthermore, none of these studies considered the 
presence of HPV. Wald et al. analyzed the influence of HPV oncogene E6 on the miRNA 
profiles in HNC cell lines (Wald et al., 2011). Lajer et al. in their first study analyzed 
nine HPV-positive oropharyngeal tumors (Lajer et al., 2011), and, a year later, they have 
published a study where they enlarged the sample set with tonsillar and cervical tumors 
(Lajer et al., 2012), which step allowed them to identify a group of “HPV-core” miRNAs 
that could have a role in HPV-related pathogenesis. Nevertheless, their studies lacked the 
confirmation of transcriptionally active HPV infection and they combined the analysis of 
FF and FFPE samples, which certainly effects the results, as discussed below. Recently, 
Miller et al. have identified a set of miRNAs deregulated in oropharyngeal carcinomas 
and validated the analysis with clinical data from The Cancer Genome Atlas (Miller et al., 
2015).  




Our study has been so far the only one to compare the miRNA data obtained from 
clinical samples with results obtained from the model system. As a model for 
HPV-associated and -independent tumors we analyzed HPV-16 immortalized 
keratinocyte clones and/or keratinocyte clones immortalized by the human telomerase 
gene. We identified groups of miRNAs specific for each group of samples, as well as 
those common for tumors/clones regardless of HPV. During the analysis of the data, we 
found out that the tumor sample homogeneity in terms of the percentage of the tumor 
cells is more important for the robustness of the miRNA expression study than the 
samples set size. Unfortunately, the overlap between clinical samples and model system 
was small and we identified concordant deregulation in only three miRNAs in each group. 
In the analysis of immortalized keratinocyte clones versus primary cells we identified 
three miRNAs (miR-135b, miR-146b-5p, miR-205-5p) whose deregulation in 
immortalized cells is in the agreement with other published studies (Al-Khalaf and 
Aboussekhra, 2014; Li Y. et al., 2015; Li J. et al., 2015). These miRNAs participate in 
signaling pathways, tumor invasion or cell migration pathways connected with EMT. The 
miRNAs identified as deregulated in clinical samples of tonsillar tumors were also 
reported to contribute to cancer development. Only miR-125b identified in the 
comparison of HPV-positive tumors versus non-malignant tissues was previously 
reported to play role in productive HPV infection (Nuovo et al., 2010).  
Due to the simultaneous analysis of miRNA expression in cervical carcinomas we 
were also able to identify a group of five miRNAs specific for HPV-induced malignancies 
(miR-141-3p, miR-15b-5p, miR-200a-3p, miR-302c-3p, and miR-9-5p). As mentioned 
above, the only study performing analogous analysis was published by Lajer et al. 
(Lajer et al., 2012). However, there was no overlap with our results, mainly because of 
the heterogeneity of their set of HNC samples as mentioned previously. Namely, their 
sample set included tumors of tonsillar as well as pharyngeal location, and also, they used 
different type of clinical samples, such as fresh frozen and formalin-fixed 
paraffin-embedded ones. The importance of the right selection of the material type is the 
subject of my third publication which is discussed below. Our results agree with Lajer´s 
only in miR-21 as the most commonly deregulated miRNA in cancers and we similarly 
identified it upregulated in HPV-associated tonsillar tumors. Further, in agreement with 
Hui et al. (Hui et al., 2013), we identified miR-9 as deregulated in HPV-related tumors 
since we determined its upregulation in both tonsillar as well as cervical tumor samples. 




The HPV-induced activation of the miR-9 expression was studied by Liu et al., who 
showed that this miRNA downregulates genes involved in pathways of cell migration and 
thus influences the motility of the cells (Liu et al., 2014). The authors observed the 
activation of miR-9 expression as a result of HPV E6 expression. MiR-9 has been 
considered as HPV-related also by Miller et al. (Miller et al., 2015).  
Further, our study was the first one which performed the miRNA analysis of 
HPV-positive tumors and keratinocyte clones based on the status of the viral genome. We 
utilized our results from the detailed characterization of samples and showed that miRNA 
expression profiles differ in tumor tissues as well as in model system with 
extrachromosomal, integrated, or mixed form of the virus. Even though there was no 
overlap in deregulated miRNAs between clinical samples and the model system, we 
found out that identified miRNAs target the same genetic pathways, such as p53 
signaling, cell cycle regulation, or PI3K-Akt signaling. Moreover, using factor analysis 
we analyzed the miRNA expression in the relation to the patient prognosis and identified 
twelve miRNAs (miR-196b, miR-485-3p, miR-589, miR-324-3p, miR-342-3p, 
miR-92a-1#, miR-155, miR-146b, miR-142-3p, miR-1260, miR-143, and miR-142-5p) 
that may influence it. Many of them have already been published as prognostic markers 
of other cancers (Lin et al., 2012; Ren et al., 2017; Xie et al., 2017), or directly in head 
and neck tumors of different locations (Xu et al., 2015; Baba et al., 2015; Jamali et al., 
2015; Bufalino et al., 2015). Nevertheless, for obtaining more reliable results, the study 
should be confirmed on a larger set of samples.   
Our further aim of research was the optimization and implementation of the 
method in situ hybridization of miRNA for determination of the miRNA location in the 
cell. Since the method performed on FF tissues requires extensive optimization of the 
process and sufficient number of prepared slices, we performed in situ hybridization on 
FFPE tissues. However, we had to confirm the miRNA expression profiles obtained from 
FF samples also on FFPE ones. Based on our experience from previous research about 
the importance of homogenous set of samples for the analyses, we performed the TLDA 
analysis on RNA isolated from macrodissected FFPE tumor samples. The results were 
compared with the miRNA expression profiles obtained from FF samples and our 
findings were published in 2017 in Plos One (Vojtechova et al., 2017). Moreover, for 
comparison, we processed the data by different software programs and we used two types 
of normalization of data.  




The possibility to utilize FFPE samples available in archives for different analysis 
offers the opportunity to perform retrospective studies, use the long-term follow-up data 
from patients and to extend the studies. The utilization of RNA from FFPE tissues is still 
challenging due to the RNA fragmentation caused by crosslinks between tissues and 
molecular components (Doleshal et al., 2008). However, in the case of small RNAs, their 
stability is not influenced by formalin fixation, probably due to their small size and 
secondary structure (Xi et al., 2007; Doleshal et al., 2008; Jung et al., 2010). Therefore, 
FFPE samples are usable for miRNA expression, as has been shown previously 
(Osawa et al., 2011; Lee et al., 2013; Ganci et al., 2014; Leichter et al., 2015), also in the 
cases when the RNA integrity number showing the quality of isolated RNA is low 
(Chatterjee et al., 2015). In our study, we performed the analysis of miRNA expression 
profiles in a set of tonsillar FFPE tumors and clinically unaffected controls and compared 
them with miRNA profiles obtained from paired FF samples. We revealed that the 
miRNA expression profiles differ between FF and FFPE samples, and, also, depending 
on the character of the tissue (tumor vs. normal tissue). We observed good correlation of 
miRNA profiles between paired FF and FFPE samples, however, the overlap between 
differentially expressed miRNAs was only 27-38 %. Macrodissected FFPE samples 
revealed less differentially expressed miRNAs compared to paired FF samples. Since our 
previous study revealed that the tumor tissue homogeneity is important for miRNA 
expression studies, we evaluated the correlation of samples based on the number of tumor 
cells. Contrary to our hypothesis, we observed no relationship. Most of the earlier 
published studies comparing FFPE and FF samples were focused only on few miRNAs 
(Li et al., 2007; Hoefig et al., 2008; Mortarino et al., 2010; Leite et al., 2011; 
de Biase et al., 2012). More recent studies utilized also microarray analyses (Hui et al., 
2009; Romero-Cordoba et al., 2012) and NGS (Meng et al., 2013). These projects have 
revealed higher correlation of miRNA profiles between paired FF and FFPE samples, 
however, the limitation of these studies was the small number of analyzed samples, or the 
lack of macrodissection of samples. Last, but not least, the studies were not done on HNC. 
On the other hand, the results of the study of How et al. made on cervical tumors agree 
with ours (How et al., 2015). They identified the miRNA signature in a cohort of FF 
samples and were unsuccessful to validate it in a cohort of FFPE samples.  
Finally, to establish how the choice of normalization method and software for data 
analysis influenced the results, we performed the comparison of two normalization 




methods (50th percentile shift normalization and global normalization) and three software 
programs (GeneSpring GX v13.1, GenEx v6.1, and MeV v4.9). The differentially 
expressed miRNAs based on each normalization method overlap in 58-67 % for FF or 
FFPE samples. On the other hand, the comparison of different software programs 
revealed the overlap in 90 % of differentially expressed miRNAs. Thus, the use of 
different type of the clinical material and normalization methods increased the variability 
of results between studies and partly explained the small overlaps in the obtained pattern 
of differentially expressed miRNAs. 
 





The submitted thesis focuses on the study of miRNA expression profiles in human 
tumors related to human papillomaviruses, such as head and neck cancer and cervical 
tumors. Because of their tissue and tumor specificity and their small size, miRNAs are 
suitable candidates for being clinical biomarkers and for improving the current diagnostic 
and therapeutic possibilities.  
My initial paper, included into this thesis, focused on the detailed characterization 
of obtained samples from cooperating clinics. We performed the analysis of viral genome 
status in tumors, because the integration of the virus into the host genome is considered 
as a critical step in carcinogenic progression. Based on our analysis we have revealed that 
in tonsillar tumors the integrated form of virus is in 36 % of samples and specified and 
described the integration sites. Furthermore, we have shown that the integration 
influences the disease specific survival of patients but not statistically significantly.  
Such characterized samples were used in the main part of my research focused on 
miRNA profiling of HPV-positive and HPV-negative tonsillar and cervical tumors. 
We characterized the miRNA expression profiles of virus-associated tumors and tumors 
of non-viral etiology and for comparison we analyzed miRNA expression profiles in the 
model system of human keratinocyte clones. During the research, several important 
observations have been made. The importance of homogeneity of analyzed samples and 
the standardization of screened material and methods of analyses of obtained data have 
been revealed. All these observations allow for improvement of the following 
experiments. Finally, the HPV-core miRNAs were identified and will be in the 
subsequent projects evaluated in a set of HPV-related and non-related tumors from other 
anatomical locations as well as analyzed functionally. 
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